Guidelines for the management of mature T-cell and NK-cell neoplasms (excluding cutaneous T-cell lymphoma)

British Journal of Haematology

Volumn 153, Issue 4, 2011, Pages 451-485

  Dearden, Claire E ^a   Johnson, Rod ^b   Pettengell, Ruth ^c   Devereux, Stephen ^d   Cwynarski, Kate ^e   Whittaker, Sean ^f   Mcmillan, Andrew ^g  

^a ROYAL MARSDEN HOSPITAL   (United Kingdom)

^b ST JAMES S UNIVERSITY HOSPITAL   (United Kingdom)

^c ST GEORGE S HOSPITAL   (United Kingdom)

^d KING S COLLEGE HOSPITAL   (United Kingdom)

^e ROYAL FREE HOSPITAL   (United Kingdom)

^f ST THOMAS HOSPITAL   (United Kingdom)

^g NOTTINGHAM UNIVERSITY HOSPITALS NHS TRUST   (United Kingdom)

Author keywords

Stem cell transplantation; T cell leukaemia; T cell lymphoma

Indexed keywords

ALEMTUZUMAB; ALPHA INTERFERON; ANTINEOPLASTIC AGENT; ASPARAGINASE; BEVACIZUMAB; BLEOMYCIN; CARMUSTINE; CISPLATIN; CLADRIBINE; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; CYTARABINE; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; FLUDARABINE; GEMCITABINE; IFOSFAMIDE; MELPHALAN; METHOTREXATE; METHYLPREDNISOLONE; MITOXANTRONE; PENTOSTATIN; PREDNISONE; PROCARBAZINE; RITUXIMAB; STEROID; THALIDOMIDE; UNINDEXED DRUG; VINCRISTINE;

AGGRESSIVE NK CELL LEUKEMIA; ALLOGENEIC STEM CELL TRANSPLANTATION; ANEMIA; ANGIOIMMUNOBLASTIC T CELL LYMPHOMA; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; BLOOD TRANSFUSION; CANCER DIAGNOSIS; CANCER INCIDENCE; CANCER STAGING; CHRONIC LYMPHATIC LEUKEMIA; COMPUTER ASSISTED TOMOGRAPHY; CUTANEOUS T CELL LYMPHOMA; CYTOGENETICS; CYTOPENIA; DONOR LYMPHOCYTE INFUSION; DRUG DOSE ESCALATION; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG MEGADOSE; ENTEROPATHY ASSOCIATED T CELL LYMPHOMA; GRAFT VERSUS HOST REACTION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEPATOSPLENIC T CELL LYMPHOMA; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LARGE CELL LYMPHOMA; LARGE GRANULAR LYMPHOCYTE LEUKEMIA; LOW DRUG DOSE; LYMPHOPROLIFERATIVE DISEASE; MATURE T CELL LEUKEMIA; MULTIPLE CYCLE TREATMENT; NK T CELL LYMPHOMA; NUCLEAR MAGNETIC RESONANCE IMAGING; OVERALL SURVIVAL; PERIPHERAL T CELL LYMPHOMA; PHENOTYPE; POLYMERASE CHAIN REACTION; POSITRON EMISSION TOMOGRAPHY; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; PROLYMPHOCYTIC LEUKEMIA; SINGLE DRUG DOSE; SUBCUTANEOUS PANNICULITIS LIKE T CELL LYMPHOMA; SYMPTOMATOLOGY; SYSTEMATIC REVIEW; T CELL LEUKEMIA; T CELL LYMPHOMA; TREATMENT RESPONSE;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; EVIDENCE-BASED MEDICINE; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; INCIDENCE; KILLER CELLS, NATURAL; LEUKEMIA, T-CELL; LYMPHOMA, T-CELL; LYMPHOMA, T-CELL, PERIPHERAL; MALE; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; YOUNG ADULT;

EID: 79955029799     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/j.1365-2141.2011.08651.x     Document Type: Article

References (319)

1. Advani, R., Horwitz, S., Zelenetz, A. & Horning, S.J. (2007) Angioimmunoblastic T cell lymphoma: treatment experience with cyclosporine. Leukaemia & Lymphoma, 48, 521-525.
2. Agostinelli, C., Piccaluga, P.P., Went, P., Rossi, M., Gazzola, A., Righi, S., Sista, T., Campidelli, C., Zinzani, P.L., Falini, B. & Pileri, S.A. (2008) Peripheral T cell lymphoma, not otherwise specified: the stuff of genes, dreams and therapies. Journal of Clinical Pathology, 61, 1160-1167.
3. Ait-Tahar, K., Cerundolo, V., Banham, A.H., Hatton, C., Blanchard, T., Kusec, R., Becker, M., Smith, G.L. & Pulford, K. (2006) B and CTL responses to the ALK protein in patients with ALK-positive ALCL. International Journal of Cancer, 118, 688-695.
4. Aldinucci, D., Poletto, D., Zagonel, V., Rupolo, M., Degan, M., Nanni, P., Gattei, V. & Pinto, A. (2000) In vitro and in vivo effects of 2'-deoxycoformycin (Pentostatin) on tumour cells from human gammadelta+ T-cell malignancies. British Journal of Haematology, 110, 188-196.
5. Alekshun, T.J., Tao, J. & Sokol, L. (2007) Aggressive T-cell large granular lymphocyte leukemia: a case report and review of the literature. American Journal of Hematology, 82, 481-485.
6. Al-toma, A., Visser, O.J., van Roessel, H.M., von Blomberg, B.M., Verbeek, W.H., Scholten, P.E., Ossenkoppele, G.J., Huijgens, P.C. & Mulder, C.J. (2007) Autologous hematopoietic stem cell transplantation in refractory celiac disease with aberrant T cells. Blood, 109, 2243-2249.
7. Ambepitiya, G.B. (1989) Angioimmunoblastic lymphadenopathy associated with thyroid disease. Journal of Clinical Pathology, 42, 668-669.
8. d'Amore, F., Relander, T., Lauritzsen, G., Jantunen, E., Hagberg, H., Anderson, H., Cavallin-Ståhl, E., Holte, H., Østerborg, A., Merup, M., Hansen, M., Telhaug, R., Erlanson, M., Kuittinen, O., Gadeberg, O., Delabie, J., Sundström, C., Ralfkiær, E., Vornanen, M. & Jensen, C.B. (2006) Dose-dense induction followed by autologous stem cell transplant (ASCT) as 1st line treatment in peripheral t-cell lymphomas (PTCL) - a phase II study of the nordic lymphoma group (NLG). Blood (ASH Annual Meeting Abstracts), 108, 401.
9. d'Amore, F., Radford, J., Relander, T., Jerkeman, M., Tilly, H., Osterborg, A., Morschhauser, F., Gramatzki, M., Dreyling, M., Bang, B. & Hagberg, H. (2010) Phase II trial of zanolimumab (HuMax-CD4) in relapsed or refractory non-cutaneous peripheral T cell lymphoma. British Journal of Haematology, 150(5), 565-73.
10. Ansell, S.M., Horwitz, S.M., Engert, A., Khan, K.D., Lin, T., Strair, R., Keler, T., Graziano, R., Blanset, D., Yellin, M., Fischkoff, S., Assad, A. & Borchmann, P. (2007) Phase I/II study of an anti-CD30 monoclonal antibody (MDX-060) in Hodgkin's lymphoma and anaplastic large-cell lymphoma. Journal of Clinical Oncology, 25, 2764-2769.
11. Arkenau, H.T., Chong, G., Cunningham, D., Watkins, D., Sirohi, B., Chau, I., Wotherspoon, A., Norman, A., Horwich, A. & Matutes, E. (2007) Gemcitabine, cisplatin and methylprednisolone for the treatment of patients with peripheral T-cell lymphoma: the Royal Marsden Hospital experience. Haematologica, 92, 271-272.
12. Arnulf, B., Copie-Bergman, C., Delfau-Larue, M.H., Lavergne-Slove, A., Bosq, J., Wechsler, J., Wassef, M., Matuchansky, C., Epardeau, B., Stern, M., Bagot, M., Reyes, F. & Gaulard, P. (1998) Nonhepatosplenic gammadelta T-cell lymphoma: a subset of cytotoxic lymphomas with mucosal or skin localization. Blood, 91, 1723-1731.
13. Arrowsmith, E.R., Macon, W.R., Kinney, M.C., Stein, R.S., Goodman, S.A., Morgan, D.S., Flexner, J.M., Cousar, J.B., Jagasia, M.H., McCurley, T.L. & Greer, J.P. (2003) Peripheral T-cell lymphomas: clinical features and prognostic factors of 92 cases defined by the revised European American lymphoma classification. Leukaemia & Lymphoma, 44, 241-249.
14. Asano, N., Suzuki, R., Kagami, Y., Ishida, F., Kitamura, K., Fukutani, H., Morishima, Y., Takeuchi, K. & Nakamura, S. (2005) Clinicopathologic and prognostic significance of cytotoxic molecule expression in nodal peripheral T-cell lymphoma, unspecified. American Journal of Surgical Pathology, 29, 1284-1293.
15. Ascani, S., Zinzani, P.L., Gherlinzoni, F., Sabattini, E., Briskomatis, A., de Vivo, A., Piccioli, M., Fraternali Orcioni, G., Pieri, F., Goldoni, A., Piccaluga, P.P., Zallocco, D., Burnelli, R., Leoncini, L., Falini, B., Tura, S. & Pileri, S.A. (1997) Peripheral T-cell lymphomas. Clinico-pathologic study of 168 cases diagnosed according to the R.E.A.L. Classification. Annals of Oncology, 8, 583-592.
16. Attygalle, A., Al-Jehani, R., Diss, T.C., Munson, P., Liu, H., Du, M.Q., Isaacson, P.G. & Dogan, A. (2002) Neoplastic T cells in angioimmunoblastic T-cell lymphoma express CD10, Blood, 99, 627-633.
17. Au, W.Y. (2010) Current management of nasal NK/T-cell lymphoma. Oncology (Williston Park), 24, 352-358.
18. Au, W.Y., Lie, A.K., Liang, R., Kwong, Y.L., Yau, C.C., Cheung, M.M., Ngan, K.C., Lau, W.H., Wong, K.H., Yiu, H.Y., Cheng, H.C., Au, K.H. & Chan, J.K. (2003) Autologous stem cell transplantation for nasal NK/T-cell lymphoma: a progress report on its value. Annals of Oncology, 14, 1673-1676.
19. Au, W.Y., Weisenburger, D.D., Intragumtornchai, T., Nakamura, S., Kim, W.S., Sng, I., Vose, J., Armitage, J.O. & Liang, R. (2009) Clinical differences between nasal and extranasal natural killer/T-cell lymphoma: a study of 136 cases from the International Peripheral T-Cell Lymphoma Project. Blood, 113, 3931-3937.
20. Aviles, A., Cleto, S., Castaneda, C. & Nambo, M.J. (2007) CMED in the treatment of nasal natural killer cell lymphoma with distant metastases. Hematology, 12, 241-244.
21. Awidi, A.S., Tarawneh, M.S., Abu Khalaf, M.S., Al Khateeb, M.S. & Amr, S.S. (1983) Therapeutic effect of vincristine, adriamycin and prednisolone (VAP) in angioimmunoblastic lymphadenopathy (AIL). Cancer Chemotherapy and Pharmacology, 10, 221-222.
22. Ballester, B., Ramuz, O., Gisselbrecht, C., Doucet, G., Loi, L., Loriod, B., Bertucci, F., Bouabdallah, R., Devilard, E., Carbuccia, N., Mozziconacci, M.J., Birnbaum, D., Brousset, P., Berger, F., Salles, G., Briere, J., Houlgatte, R., Gaulard, P. & Xerri, L. (2006) Gene expression profiling identifies molecular subgroups among nodal peripheral T-cell lymphomas. Oncogene, 25, 1560-1570.
23. Baseggio, L., Berger, F., Carret, J., Thieblemont, C., Morel, D., Magaud, J. & Felman, P. (2004) Usefulness of CD10 study by multi-colour flow cytometry in angioimmunoblastic T-cell lymphoma. Blood (ASH Annual Meeting Abstracts), 104, 4545.
24. Battiwalla, M., Melenhorst, J., Saunthararajah, Y., Nakamura, R., Molldrem, J., Young, N.S. & Barrett, A.J. (2003) HLA-DR4 predicts haematological response to cyclosporine in T-large granular lymphocyte lymphoproliferative disorders. British Journal of Haematology, 123, 449-453.
25. Bazarbachi, A. & Hermine, O. (1996) Treatment with a combination of zidovudine and alpha-interferon in naive and pretreated adult T-cell leukemia/lymphoma patients. Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology, 13(Suppl. 1), S186-S190.
26. Bazarbachi, A., Ghez, D., Lepelletier, Y., Nasr, R., de The, H., El- Sabban, M.E. & Hermine, O. (2004) New therapeutic approaches for adult T-cell leukaemia. Lancet Oncology, 5, 664-672.
27. Bazarbachi, A., Plumelle, Y., Carlos Ramos, J., Tortevoye, P., Otrock, Z., Taylor, G., Gessain, A., Harrington, W., Panelatti, G. & Hermine, O. (2010) Meta-analysis on the use of zidovudine and interferon-alfa in adult T-cell leukemia/lymphoma showing improved survival in the leukemic subtypes. J Clin Oncol., 20;28(27), 4177-83.
28. Belhadj, K., Reyes, F., Farcet, J.P., Tilly, H., Bastard, C., Angonin, R., Deconinck, E., Charlotte, F., Leblond, V., Labouyrie, E., Lederlin, P., Emile, J.F., Delmas-Marsalet, B., Arnulf, B., Zafrani, E.S. & Gaulard, P. (2003) Hepatosplenic gammadelta T-cell lymphoma is a rare clinicopathologic entity with poor outcome: report on a series of 21 patients. Blood, 102, 4261-4269.
29. ten Berge, R.L., Oudejans, J.J., Ossenkoppele, G.J., Pulford, K., Willemze, R., Falini, B., Chott, A. & Meijer, C.J. (2000) ALK expression in extranodal anaplastic large cell lymphoma favours systemic disease with (primary) nodal involvement and a good prognosis and occurs before dissemination. Journal of Clinical Pathology, 53, 445-450.
30. ten Berge, R.L., Oudejans, J.J., Ossenkoppele, G.J. & Meijer, C.J. (2003) ALK-negative systemic anaplastic large cell lymphoma: differential diagnostic and prognostic aspects--a review. Journal of Pathology, 200, 4-15.
31. Besson, C., Panelatti, G., Delaunay, C., Gonin, C., Brebion, A., Hermine, O. & Plumelle, Y. (2002) Treatment of adult T-cell leukemia-lymphoma by CHOP followed by therapy with antinucleosides, alpha interferon and oral etoposide. Leukaemia & Lymphoma, 43, 2275-2279.
32. Bishton, M.J. & Haynes, A.P. (2007) Combination chemotherapy followed by autologous stem cell transplant for enteropathy-associated T cell lymphoma. British Journal of Haematology, 136, 111-113.
33. Blystad, A.K., Enblad, G., Kvaloy, S., Berglund, A., Delabie, J., Holte, H., Carlson, K., Kvalheim, G., Bengtsson, M. & Hagberg, H. (2001) High-dose therapy with autologous stem cell transplantation in patients with peripheral T cell lymphomas. Bone Marrow Transplantation, 27, 711-716.
34. Bossard, C., Belhadj, K., Reyes, F., Martin-Garcia, N., Berger, F., Kummer, J.A., Briere, J., Baglin, A.C., Cheze, S., Bosq, J., Ribrag, V., Gisselbrecht, C., Mounier, N. & Gaulard, P. (2007) Expression of the granzyme B inhibitor PI9 predicts outcome in nasal NK/T-cell lymphoma: results of a Western series of 48 patients treated with first-line polychemotherapy within the Groupe d'Etude des Lymphomes de l'Adulte (GELA) trials. Blood, 109, 2183-2189.
35. Brearley, R.L., Chapman, J., Cullen, M.H., Horton, M.A., Stansfeld, A.G. & Waters, A.H. (1979) Haematological features of angioimmunoblastic lymphadenopathy with dysproteinaemia. Journal of Clinical Pathology, 32, 356-360.
36. Brinkman, K., van Dongen, J.J., van Lom, K., Groeneveld, K., Misere, J.F. & van der Heul, C. (1998) Induction of clinical remission in T-large granular lymphocyte leukemia with cyclosporin A, monitored by use of immunophenotyping with Vbeta antibodies. Leukemia, 12, 150-154.
37. Brito-Babapulle, V. & Catovsky, D. (1991) Inversions and tandem translocations involving chromosome 14q11 and 14q32 in T-prolymphocytic leukemia and T-cell leukemias in patients with ataxia telangiectasia. Cancer Genetics and Cytogenetics, 55, 1-9.
38. Brousset, P., Rochaix, P., Chittal, S., Rubie, H., Robert, A. & Delsol, G. (1993) High incidence of Epstein-Barr virus detection in Hodgkin's disease and absence of detection in anaplastic large-cell lymphoma in children. Histopathology, 23, 189-191.
39. Bruns, I., Fox, F., Reinecke, P., Kobbe, G., Kronenwett, R., Jung, G. & Haas, R. (2005) Complete remission in a patient with relapsed angioimmunoblastic T-cell lymphoma following treatment with bevacizumab. Leukemia, 19, 1993-1995.
40. Cellier, C., Delabesse, E., Helmer, C., Patey, N., Matuchansky, C., Jabri, B., Macintyre, E., Cerf-Bensussan, N. & Brousse, N. (2000) Refractory sprue, coeliac disease, and enteropathy-associated T-cell lymphoma. French Coeliac Disease Study Group. Lancet, 356, 203-208.
41. Cerveny, C.G., Law, C.L., McCormick, R.S., Lenox, J.S., Hamblett, K.J., Westendorf, L.E., Yamane, A.K., Petroziello, J.M., Francisco, J.A. & Wahl, A.F. (2005) Signaling via the anti-CD30 mAb SGN-30 sensitizes Hodgkin's disease cells to conventional chemotherapeutics. Leukemia, 19, 1648-1655.
42. Chan, J.K., Sin, V.C., Wong, K.F., Ng, C.S., Tsang, W.Y., Chan, C.H., Cheung, M.M. & Lau, W.H. (1997) Nonnasal lymphoma expressing the natural killer cell marker CD56: a clinicopathologic study of 49 cases of an uncommon aggressive neoplasm. Blood, 89, 4501-4513.
43. Chanan-Khan, A., Islam, T., Alam, A., Miller, K.C., Gibbs, J., Barcos, M., Czuczman, M.S., Paplham, P., Hahn, T. & McCarthy, P. (2004) Long-term survival with allogeneic stem cell transplant and donor lymphocyte infusion following salvage therapy with anti-CD52 monoclonal antibody (Campath) in a patient with alpha/beta hepatosplenic T-cell non-Hodgkin's lymphoma. Leukaemia & Lymphoma, 45, 1673-1675.
44. Chang, S.T., Lu, C.L. & Chuang, S.S. (2007) CD52 expression in non-mycotic T- and NK/T-cell lymphomas. Leukaemia & Lymphoma, 48, 117-121.
45. Cheung, M.M., Chan, J.K., Lau, W.H., Ngan, R.K. & Foo, W.W. (2002) Early stage nasal NK/T-cell lymphoma: clinical outcome, prognostic factors, and the effect of treatment modality. International Journal of Radiation Oncology, Biology, Physics, 54, 182-190.
46. Chim, C.S., Ma, S.Y., Au, W.Y., Choy, C., Lie, A.K., Liang, R., Yau, C.C. & Kwong, Y.L. (2004) Primary nasal natural killer cell lymphoma: long-term treatment outcome and relationship with the International Prognostic Index. Blood, 103, 216-221.
47. Christensen, J.G., Zou, H.Y., Arango, M.E., Li, Q., Lee, J.H., McDonnell, S.R., Yamazaki, S., Alton, G.R., Mroczkowski, B. & Los, G. (2007) Cytoreductive antitumor activity of PF-2341066, a novel inhibitor of anaplastic lymphoma kinase and c-Met, in experimental models of anaplastic large-cell lymphoma. Molecular Cancer Therapeutics, 6, 3314-3322.
48. Coiffier, B., Brousse, N., Peuchmaur, M., Berger, F., Gisselbrecht, C., Bryon, P.A. & Diebold, J. (1990) Peripheral T-cell lymphomas have a worse prognosis than B-cell lymphomas: a prospective study of 361 immunophenotyped patients treated with the LNH-84 regimen. The GELA (Groupe d'Etude des Lymphomes Agressives). Annals of Oncology, 1, 45-50.
49. Collins, R.H., Pineiro, L.A., Agura, E.D. & Fay, J.W. (1998) Treatment of T prolymphocytic leukemia with allogeneic bone marrow transplantation. Bone Marrow Transplantation, 21, 627-628.
50. Cooke, C.B., Krenacs, L., Stetler-Stevenson, M., Greiner, T.C., Raffeld, M., Kingma, D.W., Abruzzo, L., Frantz, C., Kaviani, M. & Jaffe, E.S. (1996) Hepatosplenic T-cell lymphoma: a distinct clinicopathologic entity of cytotoxic gamma delta T-cell origin. Blood, 88, 4265-4274.
51. Corazzelli, G., Capobianco, G., Russo, F., Frigeri, F., Aldinucci, D. & Pinto, A. (2005) Pentostatin (2'-deoxycoformycin) for the treatment of hepatosplenic gammadelta T-cell lymphomas. Haematologica, 90, ECR14.
52. Corradini, P., Dodero, A., Zallio, F., Caracciolo, D., Casini, M., Bregni, M., Narni, F., Patriarca, F., Boccadoro, M., Benedetti, F., Rambaldi, A., Gianni, A.M. & Tarella, C. (2004) Graft-versus-lymphoma effect in relapsed peripheral T-cell non-Hodgkin's lymphomas after reduced-intensity conditioning followed by allogeneic transplantation of hematopoietic cells. Journal of Clinical Oncology, 22, 2172-2176.
53. Corradini, P., Tarella, C., Zallio, F., Dodero, A., Zanni, M., Valagussa, P., Gianni, A.M., Rambaldi, A., Barbui, T. & Cortelazzo, S. (2006) Long-term follow-up of patients with peripheral T-cell lymphomas treated up-front with high-dose chemotherapy followed by autologous stem cell transplantation. Leukemia, 20, 1533-1538.
54. Cuadros, M., Dave, S.S., Jaffe, E.S., Honrado, E., Milne, R., Alves, J., Rodriguez, J., Zajac, M., Benitez, J., Staudt, L.M. & Martinez-Delgado, B. (2007) Identification of a proliferation signature related to survival in nodal peripheral T-cell lymphomas. Journal of Clinical Oncology, 25, 3321-3329.
55. Dang, N.H., Pro, B., Hagemeister, F.B., Samaniego, F., Jones, D., Samuels, B.I., Rodriguez, M.A., Goy, A., Romaguera, J.E., McLaughlin, P., Tong, A.T., Turturro, F., Walker, P.L. & Fayad, L. (2007) Phase II trial of denileukin diftitox for relapsed/refractory T-cell non-Hodgkin lymphoma. British Journal of Haematology, 136, 439-447.
56. Datta, A., Bellon, M., Sinha-Datta, U., Bazarbachi, A., Lepelletier, Y., Canioni, D., Waldmann, T.A., Hermine, O. & Nicot, C. (2006) Persistent inhibition of telomerase reprograms adult T-cell leukemia to p53-dependent senescence. Blood, 108, 1021-1029.
57. Dearden, C. (2006) The role of alemtuzumab in the management of T-cell malignancies. Seminars in Oncology, 33, S44-S52.
58. Dearden, C.E. (2009) T-cell prolymphocytic leukaemia. Clinical Lymphoma & Myeloma, 9(Suppl. 3), S239-S243.
59. Dearden, C.E., Matutes, E., Cazin, B., Tjonnfjord, G.E., Parreira, A., Nomdedeu, B., Leoni, P., Clark, F.J., Radia, D., Rassam, S.M., Roques, T., Ketterer, N., Brito-Babapulle, V., Dyer, M.J. & Catovsky, D. (2001) High remission rate in T-cell prolymphocytic leukemia with CAMPATH-1H. Blood, 98, 1721-1726.
60. Delmer, A., Mounier, N., Gaulard, P., Bouabdallah, R., Hermine, O., Salles, G., Emile, J.F., Casasnovas, O., Tilly, H., Gisselbrecht, C. & Groupe d'Etude des Lymphomes de l'Adulte (2003) Intensified induction therapy with etoposide (VP16) and high-dose Cytarabine (Ara-C) in patients aged less than 60years with peripheral T cell/NK lymphoma. Preliminary results of phase II GELA study LNH98T7. Proceedings of the American Society of Clinical Oncology 22, (Abstract 2375).
61. Dhedin, N., Giraudier, S., Gaulard, P., Esperou, H., Ifrah, N., Michallet, M., Milpied, N., Rio, B., Cahn, J.Y., Molina, L., Laporte, J.L., Guilhot, F. & Kuentz, M. (1999) Allogeneic bone marrow transplantation in aggressive non-Hodgkin's lymphoma (excluding Burkitt and lymphoblastic lymphoma): a series of 73 patients from the SFGM database. Societ Francaise de Greffe de Moelle. British Journal of Haematology, 107, 154-161.
62. Dogan, A., Attygalle, A.D. & Kyriakou, C. (2003) Angioimmunoblastic T-cell lymphoma. British Journal of Haematology, 121, 681-691.
63. Dogan, A., Ngu, L.S., Ng, S.H. & Cervi, P.L. (2005) Pathology and clinical features of angioimmunoblastic T-cell lymphoma after successful treatment with thalidomide. Leukemia, 19, 873-875.
64. Domm, J.A., Thompson, M., Kuttesch, J.F., Acra, S. & Frangoul, H. (2005) Allogeneic bone marrow transplantation for chemotherapy-refractory hepatosplenic gammadelta T-cell lymphoma: case report and review of the literature. Journal of Pediatric Hematology/oncology, 27, 607-610.
65. Egashira, M., Kawamata, N., Sugimoto, K., Kaneko, T. & Oshimi, K. (1999) P-glycoprotein expression on normal and abnormally expanded natural killer cells and inhibition of P-glycoprotein function by cyclosporin A and its analogue, PSC833, Blood, 93, 599-606.
66. Elstrom, R., Guan, L., Baker, G., Nakhoda, K., Vergilio, J.A., Zhuang, H., Pitsilos, S., Bagg, A., Downs, L., Mehrotra, A., Kim, S., Alavi, A. & Schuster, S.J. (2003) Utility of FDG-PET scanning in lymphoma by WHO classification. Blood, 101, 3875-3876.
67. Emmanouilides, C., Colovos, C., Pinter-Brown, L., Hernandez, L., Schiller, G., Territo, M. & Rosen, P. (2004) Pilot study of fixed-infusion rate gemcitabine with Cisplatin and dexamethasone in patients with relapsed or refractory lymphoma. Clinical Lymphoma, 5, 45-49.
68. Enblad, G., Hagberg, H., Erlanson, M., Lundin, J., MacDonald, A.P., Repp, R., Schetelig, J., Seipelt, G. & Osterborg, A. (2004) A pilot study of alemtuzumab (anti-CD52 monoclonal antibody) therapy for patients with relapsed or chemotherapy-refractory peripheral T-cell lymphomas. Blood, 103, 2920-2924.
69. Escalon, M.P., Liu, N.S., Yang, Y., Hess, M., Walker, P.L., Smith, T.L. & Dang, N.H. (2005) Prognostic factors and treatment of patients with T-cell non-Hodgkin lymphoma: the M. D. Anderson Cancer Center experience. Cancer, 103, 2091-2098.
70. Falini, B., Pileri, S., De Solas, I., Martelli, M.F., Mason, D.Y., Delsol, G., Gatter, K.C. & Fagioli, M. (1990) Peripheral T-cell lymphoma associated with hemophagocytic syndrome. Blood, 75, 434-444.
71. Falini, B., Pileri, S., Zinzani, P.L., Carbone, A., Zagonel, V., Wolf-Peeters, C., Verhoef, G., Menestrina, F., Todeschini, G., Paulli, M., Lazzarino, M., Giardini, R., Aiello, A., Foss, H.D., Araujo, I., Fizzotti, M., Pelicci, P.G., Flenghi, L., Martelli, M.F. & Santucci, A. (1999) ALK+ lymphoma: clinico-pathological findings and outcome. Blood, 93, 2697-2706.
72. Feremans, W.W. & Khodadadi, E. (1987) Alpha-interferon therapy in refractory angioimmunoblastic lymphadenopathy. European Journal of Haematology, 39, 91.
73. Feyler, S., Prince, H.M., Pearce, R., Towlson, K., Nivison-Smith, I., Schey, S., Gibson, J., Patton, N., Bradstock, K., Marks, D.I. & Cook, G. (2007) The role of high-dose therapy and stem cell rescue in the management of T-cell malignant lymphomas: a BSBMT and ABMTRR study. Bone Marrow Transplantation, 40, 443-450.
74. Forero-Torres, A., Leonard, J.P., Younes, A., Rosenblatt, J.D., Brice, P., Bartlett, N.L., Bosly, A., Pinter-Brown, L., Kennedy, D., Sievers, E.L. & Gopal, A.K. (2009) A Phase II study of SGN-30 (anti-CD30 mAb) in Hodgkin lymphoma or systemic anaplastic large cell lymphoma. British Journal of Haematology, 146, 171-179.
75. Fortune, A.F., Kelly, K., Sargent, J., O'Brien, D., Quinn, F., Chadwick, N., Flynn, C., Conneally, E., Browne, P., Crotty, G.M., Thornton, P. & Vandenberghe, E. (2010) Large granular lymphocyte leukemia: natural history and response to treatment. Leukaemia & Lymphoma, 51, 839-845.
76. Foss, F.M. (2010) Enhancing existing approaches to peripheral T-cell lymphoma. Seminars in Hematology, 47(Suppl. 1), S8-S10.
77. Foss, H.D., Araujo, I., Demel, G., Klotzbach, H., Hummel, M. & Stein, H. (1997) Expression of vascular endothelial growth factor in lymphomas and Castleman's disease. Journal of Pathology, 183, 44-50.
78. Foss, F., Sjak-Shie, N., Goy, A., Jacobsen, E., Advani, R., Smith, M., Komrokji, R., Pendergrass, K., Bolejack, V., Watts, K. & Acosta, M. (2007) Denileukin diftitox (ONTAK) plus CHOP chemotherapy in patients with peripheral T-cell lymphomas (PTCL), the CONCEPT trial. Blood (ASH Annual Meeting Abstracts), 110, 3449.
79. Fujiwara, H., Arima, N., Akasaki, Y., Ohtsubo, H., Ozaki, A., Kukita, T., Matsushita, K., Arimura, K., Suruga, Y., Wakamatsu, S., Matsumoto, T., Hidaka, S., Eizuru, Y. & Tei, C. (2002) Interferon-alpha therapy following autologous peripheral blood stem cell transplantation for adult T cell leukemia/lymphoma. Acta Haematologica, 107, 213-219.
80. Fukushima, T., Miyazaki, Y., Honda, S., Kawano, F., Moriuchi, Y., Masuda, M., Tanosaki, R., Utsunomiya, A., Uike, N., Yoshida, S., Okamura, J. & Tomonaga, M. (2005) Allogeneic hematopoietic stem cell transplantation provides sustained long-term survival for patients with adult T-cell leukemia/lymphoma. Leukemia, 19, 829-834.
81. Gale, J., Simmonds, P.D., Mead, G.M., Sweetenham, J.W. & Wright, D.H. (2000) Enteropathy-type intestinal T-cell lymphoma: clinical features and treatment of 31 patients in a single center. Journal of Clinical Oncology, 18, 795-803.
82. Gallamini, A., Stelitano, C., Calvi, R., Bellei, M., Mattei, D., Vitolo, U., Morabito, F., Martelli, M., Brusamolino, E., Iannitto, E., Zaja, F., Cortelazzo, S., Rigacci, L., Devizzi, L., Todeschini, G., Santini, G., Brugiatelli, M. & Federico, M. (2004) Peripheral T-cell lymphoma unspecified (PTCL-U): a new prognostic model from a retrospective multicentric clinical study. Blood, 103, 2474-2479.
83. Gallamini, A., Zaja, F., Patti, C., Billio, A., Specchia, M.R., Tucci, A., Levis, A., Manna, A., Secondo, V., Rigacci, L., Pinto, A., Iannitto, E., Zoli, V., Torchio, P., Pileri, S. & Tarella, C. (2007) Alemtuzumab (Campath-1H) and CHOP chemotherapy as first-line treatment of peripheral T-cell lymphoma: results of a GITIL (Gruppo Italiano Terapie Innovative nei Linfomi) prospective multicenter trial. Blood, 110, 2316-2323.
84. Garderet, L., Bittencourt, H., Kaliski, A., Daniel, M., Ribaud, P., Socie, G. & Gluckman, E. (2001) Treatment of T-prolymphocytic leukemia with nonmyeloablative allogeneic stem cell transplantation. European Journal of Haematology, 66, 137-139.
85. Gascoyne, R.D., Aoun, P., Wu, D., Chhanabhai, M., Skinnider, B.F., Greiner, T.C., Morris, S.W., Connors, J.M., Vose, J.M., Viswanatha, D.S., Coldman, A. & Weisenburger, D.D. (1999) Prognostic significance of anaplastic lymphoma kinase (ALK) protein expression in adults with anaplastic large cell lymphoma. Blood, 93, 3913-3921.
86. Georgakis, G.V. & Younes, A. (2005) Heat-shock protein 90 inhibitors in cancer therapy: 17AAG and beyond. Future Oncology, 1, 273-281.
87. Gerlando, Q., Barbera, V., Ammatuna, E., Franco, V., Florena, A.M. & Mariani, G. (2000) Successful ttreatment of angioimmunoblastic lymphadenopathy with dysproteinemia-type T-cell lymphoma by combined methotrexate and prednisone. Haematologica, 85, 880-881.
88. Gill, P.S., Harrington, Jr, W., Kaplan, M.H., Ribeiro, R.C., Bennett, J.M., Liebman, H.A., Bernstein-Singer, M., Espina, B.M., Cabral, L., Allen Kornblau, S.S., Pike, M.C. & Levine, A.M. (1995) Treatment of adult T-cell leukemia-lymphoma with a combination of interferon alfa and zidovudine. New England Journal of Medicine, 332, 1744-1748.
89. Gisselbrecht, C., Gaulard, P., Lepage, E., Coiffier, B., Briere, J., Haioun, C., Cazals-Hatem, D., Bosly, A., Xerri, L., Tilly, H., Berger, F., Bouhabdallah, R. & Diebold, J. (1998) Prognostic significance of T-cell phenotype in aggressive non-Hodgkin's lymphomas. Groupe d'Etudes des Lymphomes de l'Adulte (GELA). Blood, 92, 76-82.
90. Go, R.S. & Wester, S.M. (2004) Immunophenotypic and molecular features, clinical outcomes, treatments, and prognostic factors associated with subcutaneous panniculitis-like T-cell lymphoma: a systematic analysis of 156 patients reported in the literature. Cancer, 101, 1404-1413.
91. Gressin, R., Peoch, M., Deconinck, E., Casassus, P., Desablens, B., Senecal, D., Quitet, P., Vilque, J.P., Foussard, C., Eghbali, H., Jaubert, J., Tournilhac, O., Lucas, V., Delwail, V., Choufi, B., Thyss, A., Huguet, F., Maloisel, F., Richard, B., Milpied, N.J. & Colombat, P. (2006) The VIP-ABVD regimen is not superior to the CHOP 21 for the treatment of non epidermotropic peripheral T cell lymphoma. Final results of the "LTP95" protocol of the GOELAMS. Blood (ASH Annual Meeting Abstracts), 108, 2464.
92. Grigg, A.P. (2001) 2'-Deoxycoformycin for hepatosplenic gammadelta T-cell lymphoma. Leukaemia & Lymphoma, 42, 797-799.
93. Grigg, A. (2006) Daclizumab in anaplastic large cell lymphoma. Leukaemia & Lymphoma, 47, 175.
94. Gutierrez, A., Solano, C., Ferrandez, A., Marugan, I., Terol, M.J., Benet, I., Tormo, M., Bea, M.D. & Rodriguez, J. (2003) Peripheral T-cell lymphoma associated consecutively with hemophagocytic lymphohistiocytosis and hypereosinophilic syndrome. European Journal of Haematology, 71, 303-306.
95. Hagberg, H., Pettersson, M., Bjerner, T. & Enblad, G. (2005) Treatment of a patient with a nodal peripheral T-cell lymphoma (angioimmunoblastic T-Cell lymphoma) with a human monoclonal antibody against the CD4 antigen (HuMax-CD4). Medical Oncology, 22, 191-194.
96. Halene, S., Zieske, A. & Berliner, N. (2006) Sustained remission from angioimmunoblastic T-cell lymphoma induced by alemtuzumab. Nature Clinical Practice Oncology, 3, 165-168; quiz 169.
97. Hamblett, K.J., Barton, J., Cerveny, C.G., Andreyka, J.B., Kissler, K.M., Okeley, N.M., Stone, I., Sutherland, M.K., Sun, M.M., Senter, P.D., Wahl, A.F. & Ihle, N.C. (2005) SGN-35, an anti-CD30 antibody-drug conjugate, exhibits potent antitumor activity for the treatment of CD30+ malignancies. Blood (ASH Annual Meeting Abstracts), 106, 610.
98. Hamidou, M.A., El Kouri, D., Audrain, M. & Grolleau, J.Y. (2001) Systemic antineutrophil cytoplasmic antibody vasculitis associated with lymphoid neoplasia. Annals of the Rheumatic Diseases, 60, 293-295.
99. Hammond, P.W., Vafa, O., Jacinto, J., Vielmetter, J., Karki, S., Yoder, S., Lazar, G., Raturi, D., Mollet, M., Zhu, M., Kunkel, L. & Carmichael, D. (2005) A humanized anti-CD30 monoclonal antibody, XmAbTM2513, with enhanced in vitro potency against CD30-positive lymphomas mediated by high affinity Fc-receptor binding. Blood (ASH Annual Meeting Abstracts), 106, 1470.
100. Harabuchi, Y., Imai, S., Wakashima, J., Hirao, M., Kataura, A., Osato, T. & Kon, S. (1996) Nasal T-cell lymphoma causally associated with Epstein-Barr virus: clinicopathologic, phenotypic, and genotypic studies. Cancer, 77, 2137-2149.
101. Harashima, N., Kurihara, K., Utsunomiya, A., Tanosaki, R., Hanabuchi, S., Masuda, M., Ohashi, T., Fukui, F., Hasegawa, A., Masuda, T., Takaue, Y., Okamura, J. & Kannagi, M. (2004) Graft-versus-Tax response in adult T-cell leukemia patients after hematopoietic stem cell transplantation. Cancer Research, 64, 391-399.
102. Harris, N.L., Jaffe, E.S., Diebold, J., Flandrin, G., Muller- Hermelink, H.K., Vardiman, J., Lister, T.A. & Bloomfield, C.D. (1999) The World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues. Report of the Clinical Advisory Committee meeting, Airlie House, Virginia, November, 1997. Annals of Oncology, 10, 1419-1432.
103. Hasserjian, R.P. & Harris, N.L. (2007) NK-cell lymphomas and leukemias: a spectrum of tumors with variable manifestations and immunophenotype. American Journal of Clinical Pathology, 127, 860-868.
104. Hast, R. & Gustafsson, B. (1991) Improved response to chemotherapy after interferon alpha-2b in angioimmunoblastic lymphadenopathy (AILD). European Journal of Haematology, 46, 51-52.
105. Hast, R., Jacobsson, B., Petrescu, A. & Hjalmar, V. (1999) Successful treatment with fludarabine in two cases of angioimmunoblastic lymphadenopathy with dysproteinemia. Leukaemia & Lymphoma, 34, 597-601.
106. He, S., Roberts, A., Ritchie, D. & Grigg, A. (2007) Graft-versus-lymphoma effect in progressive hepatosplenic gamma/delta T-cell lymphoma. Leukaemia & Lymphoma, 48, 1448-1450.
107. Hermine, O., Bouscary, D., Gessain, A., Turlure, P., Leblond, V., Franck, N., Buzyn-Veil, A., Rio, B., Macintyre, E., Dreyfus, F. & Bazarbachi, A. (1995) Brief report: treatment of adult T-cell leukemia-lymphoma with zidovudine and interferon alfa. New England Journal of Medicine, 332, 1749-1751.
108. Hermine, O., Allard, I., Levy, V., Arnulf, B., Gessain, A. & Bazarbachi, A. (2002) A prospective phase II clinical trial with the use of zidovudine and interferon-alpha in the acute and lymphoma forms of adult T-cell leukemia/lymphoma. The Hematology Journal, 3, 276-282.
109. Hermine, O., Dombret, H., Poupon, J., Arnulf, B., Lefrere, F., Rousselot, P., Damaj, G., Delarue, R., Fermand, J.P., Brouet, J.C., Degos, L., Varet, B., de The, H. & Bazarbachi, A. (2004) Phase II trial of arsenic trioxide and alpha interferon in patients with relapsed/refractory adult T-cell leukemia/lymphoma. The Hematology Journal, 5, 130-134.
110. Hill, Q.A. & Owen, R.G. (2006) CNS prophylaxis in lymphoma: who to target and what therapy to use. Blood Reviews, 20, 319-332.
111. Hopfinger, G., Busch, R., Barbara, E., Paula, C., Gabriele, K., Gunther, F.R., Fink, A.M., Stephan, S. & Hallek, M. (2007) TPLL-1 protocol of the German CLL Study Group (GCLLSG) - A prospective phase II trial of fludarabine phosphate, mitoxantrone and cyclophosphamide (FMC) followed by alemtuzumab consolidation in T-PLL. Blood (ASH Annual Meeting Abstracts), 110, 2039.
112. Hoque, S.R., Child, F.J., Whittaker, S.J., Ferreira, S., Orchard, G., Jenner, K., Spittle, M. & Russell-Jones, R. (2003) Subcutaneous panniculitis-like T-cell lymphoma: a clinicopathological, immunophenotypic and molecular analysis of six patients. British Journal of Dermatology, 148, 516-525.
113. Horwitz, S.M., Foss, F., Goldfarb, S., Molina, A., Hamlin, P.A., O'Connor, O.A., Cammarata, M., Moskowitz, C.H. & Zelenetz, A.D. (2006) FDG-PET scans as a staging study for T-Cell lymphomas: high rates of positivity do not result in frequent changes in stage. Blood (ASH Annual Meeting Abstracts), 108, 2399.
114. Hsu, F.Y., Zhao, Y., Anderson, W.F. & Johnston, P.B. (2007) Downregulation of NPM-ALK by siRNA causes anaplastic large cell lymphoma cell growth inhibition and augments the anti cancer effects of chemotherapy in vitro. Cancer Investigation, 25, 240-248.
115. Huang, M.J., Jiang, Y., Liu, W.P., Li, Z.P., Li, M., Zhou, L., Xu, Y., Yu, C.H., Li, Q., Peng, F., Liu, J.Y., Luo, F. & Lu, Y. (2008) Early or up-front radiotherapy improved survival of localized extranodal NK/T-cell lymphoma, nasal-type in the upper aerodigestive tract. International Journal of Radiation Oncology, Biology, Physics, 70, 166-174.
116. Huang, W.T., Huang, C.C., Weng, S.W. & Eng, H.L. (2009) Expression of the multidrug resistance protein MRP and the lung-resistance protein LRP in nasal NK/T cell lymphoma: further exploring the role of P53 and WT1 gene. Pathology, 41, 127-132.
117. Huang, Y., de Reynies, A., de Leval, L., Ghazi, B., Martin-Garcia, N., Travert, M., Bosq, J., Briere, J., Petit, B., Thomas, E., Coppo, P., Marafioti, T., Emile, J.F., Delfau- Larue, M.H., Schmitt, C. & Gaulard, P. (2010) Gene expression profiling identifies emerging oncogenic pathways operating in extranodal NK/T-cell lymphoma, nasal type. Blood, 115, 1226-1237.
118. Iannitto, E., Barbera, V., Quintini, G., Cirrincione, S. & Leone, M. (2002) Hepatosplenic gammadelta T-cell lymphoma: complete response induced by treatment with pentostatin. British Journal of Haematology, 117, 995-996.
119. Iqbal, J., Kucuk, C., Deleeuw, R.J., Srivastava, G., Tam, W., Geng, H., Klinkebiel, D., Christman, J.K., Patel, K., Cao, K., Shen, L., Dybkaer, K., Tsui, I.F., Ali, H., Shimizu, N., Au, W.Y., Lam, W.L. & Chan, W.C. (2009) Genomic analyses reveal global functional alterations that promote tumor growth and novel tumor suppressor genes in natural killer-cell malignancies. Leukemia, 23, 1139-1151.
120. Iqbal, J., Weisenburger, D.D., Greiner, T.C., Vose, J.M., McKeithan, T., Kucuk, C., Geng, H., Deffenbacher, K., Smith, L., Dybkaer, K., Nakamura, S., Seto, M., Delabie, J., Berger, F., Loong, F., Au, W.Y., Ko, Y.H., Sng, I., Armitage, J.O. & Chan, W.C. (2010a) Molecular signatures to improve diagnosis in peripheral T-cell lymphoma and prognostication in angioimmunoblastic T-cell lymphoma. Blood, 115, 1026-1036.
121. Iqbal, J., Weisenburger, D.D., Chowdhury, A., Tsai, M.Y., Srivastava, G., Greiner, T.C., Kucuk, C., Deffenbacher, K., Vose, J., Smith, L., Au, W.Y., Nakamura, S., Seto, M., Delabie, J., Berger, F., Loong, F., Ko, Y.H., Sng, I., Liu, X., Loughran, T.P., Armitage, J. & Chan, W.C. (2011) Natural killer cell lymphoma shares strikingly similar molecular features with a group of non-hepatosplenic gammadelta T-cell lymphoma and is highly sensitive to a novel aurora kinase A inhibitor in vitro. Leukemia, 25, 348-358.
122. Ishida, T. & Ueda, R. (2006) CCR4 as a novel molecular target for immunotherapy of cancer. Cancer Science, 97, 1139-1146.
123. Ishida, T., Inagaki, H., Utsunomiya, A., Takatsuka, Y., Komatsu, H., Iida, S., Takeuchi, G., Eimoto, T., Nakamura, S. & Ueda, R. (2004) CXC chemokine receptor 3 and CC chemokine receptor 4 expression in T-cell and NK-cell lymphomas with special reference to clinicopathological significance for peripheral T-cell lymphoma, unspecified. Clinical Cancer Research, 10, 5494-5500.
124. Jaccard, A., Petit, B., Girault, S., Suarez, F., Gressin, R., Zini, J.M., Coiteux, V., Larroche, C., Devidas, A., Thieblemont, C., Gaulard, P., Marin, B., Gachard, N., Bordessoule, D. & Hermine, O. (2009) L-asparaginase-based treatment of 15 western patients with extranodal NK/T-cell lymphoma and leukemia and a review of the literature. Annals of Oncology, 20, 110-116.
125. Jaeger, G., Bauer, F., Brezinschek, R., Beham-Schmid, C., Mannhalter, C. & Neumeister, P. (2008) Hepatosplenic gammadelta T-cell lymphoma successfully treated with a combination of alemtuzumab and cladribine. Annals of Oncology, 19, 1025-1026.
126. Jagasia, M., Morgan, D., Goodman, S., Hamilton, K., Kinney, M., Shyr, Y., Stein, R., Zic, J. & Greer, J. (2004) Histology impacts the outcome of peripheral T-cell lymphomas after high dose chemotherapy and stem cell transplant. Leukaemia & Lymphoma, 45, 2261-2267.
127. Janik, J.E., Dunleavy, K., Pittaluga, S., Jaffe, E.S., Grant, N., Shovlin, M., Stetler-Stevenson, M. & Wilson, W.H. (2005) A pilot trial of campath-1H and dose-adjusted EPOCH in CD52-expressing aggressive T-cell malignancies. Blood (ASH Annual Meeting Abstracts), 106, 3348.
128. Jantunen, E., Siitonen, T., Putkonen, M., Koivunen, E., Juvonen, E., Nousiainen, T. & Koistinen, P. (2004) Autologous stem cell transplantation in patients with primary amyloidosis: a nation-wide survey. Leukaemia & Lymphoma, 45, 2485-2489.
129. Jerkeman, M., Anderson, H., Cavallin-Stahl, E., Dictor, M., Hagberg, H., Johnson, A., Kaasa, S., Kvaloy, S., Sundstrom, C. & Akerman, M. (1999) CHOP versus MACOP-B in aggressive lymphoma - a Nordic Lymphoma Group randomised trial. Annals of Oncology, 10, 1079-1086.
130. Jiang, L., Yuan, C.M., Hubacheck, J., Janik, J.E., Wilson, W., Morris, J.C., Jasper, G.A. & Stetler-Stevenson, M. (2009) Variable CD52 expression in mature T cell and NK cell malignancies: implications for alemtuzumab therapy. British Journal of Haematology, 145, 173-179.
131. Joly, B., Frenkel, V., Belhadj, K., El Gnaoui, T., Rahmouni, A., Gaulard, P., Delfau- Larue, M.H., Reyes, F. & Haioun, C. (2004) Rituximab in combination with CHOP regimen in T-cell angioimmunoblastic lymphoma (AILD-TL) rich in large B cells. Favourable results in four patients. [Abstract] J.Clin.Oncol, 22, 6694.
132. Kaluza, V., Rao, D.S., Said, J.W. & de Vos, S. (2006) Primary extranodal nasal-type natural killer/T-cell lymphoma of the brain: a case report. Human Pathology, 37, 769-772.
133. Kami, M., Hamaki, T., Miyakoshi, S., Murashige, N., Kanda, Y., Tanosaki, R., Takaue, Y., Taniguchi, S., Hirai, H., Ozawa, K. & Kasai, M. (2003) Allogeneic haematopoietic stem cell transplantation for the treatment of adult T-cell leukaemia/lymphoma. British Journal of Haematology, 120, 304-309.
134. Karakas, T., Bergmann, L., Stutte, H.J., Jager, E., Knuth, A., Weidmann, E., Mitrou, P.S. & Hoelzer, D. (1996) Peripheral T-cell lymphomas respond well to vincristine, adriamycin, cyclophosphamide, prednisone and etoposide (VACPE) and have a similar outcome as high-grade B-cell lymphomas. Leukaemia & Lymphoma, 24, 121-129.
135. Kato, K., Kanda, Y., Eto, T., Muta, T., Gondo, H., Taniguchi, S., Shibuya, T., Utsunomiya, A., Kawase, T., Kato, S., Morishima, Y., Kodera, Y. & Harada, M. (2007) Allogeneic bone marrow transplantation from unrelated human T-cell leukemia virus-I-negative donors for adult T-cell leukemia/lymphoma: retrospective analysis of data from the Japan Marrow Donor Program. Biology of Blood and Marrow Transplantation, 13, 90-99.
136. Kawa-Ha, K., Ishihara, S., Ninomiya, T., Yumura-Yagi, K., Hara, J., Murayama, F., Tawa, A. & Hirai, K. (1989) CD3-negative lymphoproliferative disease of granular lymphocytes containing Epstein-Barr viral DNA. Journal of Clinical Investigation, 84, 51-55.
137. Keating, M.J., Cazin, B., Coutre, S., Birhiray, R., Kovacsovics, T., Langer, W., Leber, B., Maughan, T., Rai, K., Tjonnfjord, G., Bekradda, M., Itzhaki, M. & Herait, P. (2002) Campath-1H treatment of T-cell prolymphocytic leukemia in patients for whom at least one prior chemotherapy regimen has failed. Journal of Clinical Oncology, 20, 205-213.
138. Kewalramani, T., Zelenetz, A.D., Teruya-Feldstein, J., Hamlin, P., Yahalom, J., Horwitz, S., Nimer, S.D. & Moskowitz, C.H. (2006) Autologous transplantation for relapsed or primary refractory peripheral T-cell lymphoma. British Journal of Haematology, 134, 202-207.
139. Khong, P.L., Pang, C.B., Liang, R., Kwong, Y.L. & Au, W.Y. (2008) Fluorine-18 fluorodeoxyglucose positron emission tomography in mature T-cell and natural killer cell malignancies. Annals of Hematology, 87, 613-621.
140. Kim, G.E., Yang, W.I., Lee, S.W., Rha, S.Y., Chung, H.C., Kim, J.H., Cho, J.H., Suh, C.O., Yoo, N.C., Roh, J.K. & Hahn, J.S. (2004) Lack of correlation between P-glycoprotein and chemotherapy resistance in nasal NK/T-cell lymphomas. Leukaemia & Lymphoma, 45, 1857-1864.
141. Kim, H.J., Bang, S.M., Lee, J., Kwon, H.C., Suh, C., Lee, J.H., Ryoo, B.Y., Park, Y.H., Kwon, J.M., Oh, S.Y., Lee, H.R., Kim, K., Jung, C.W., Park, K. & Kim, W.S. (2006) High-dose chemotherapy with autologous stem cell transplantation in extranodal NK/T-cell lymphoma: a retrospective comparison with non-transplantation cases. Bone Marrow Transplantation, 37, 819-824.
142. Kim, H.S., Kim, K.H., Chang, M.H., Ji, S.H., Lim do, H., Kim, K., Kim, S.J., Ko, Y., Ki, C.S., Jo, S.J., Lee, J.W. & Kim, W.S. (2009) Whole blood Epstein-Barr virus DNA load as a diagnostic and prognostic surrogate: extranodal natural killer/T-cell lymphoma. Leukaemia & Lymphoma, 50, 757-763.
143. Kim, J.G., Sohn, S.K., Chae, Y.S., Kim, D.H., Baek, J.H., Lee, K.B., Lee, J.J., Chung, I.J., Kim, H.J., Yang, D.H., Lee, W.S., Joo, Y.D. & Sohn, C.H. (2006) CHOP plus etoposide and gemcitabine (CHOP-EG) as front-line chemotherapy for patients with peripheral T cell lymphomas. Cancer Chemotherapy and Pharmacology, 58, 35-39.
144. Kim, J.G., Sohn, S.K., Chae, Y.S., Cho, Y.Y., Yang, D.H., Lee, J.J., Kim, H.J., Shin, H.J., Chung, J.S., Cho, G.J., Lee, W.S., Joo, Y.D., Sohn, C.H. & Oh, S.J. (2007) Alemtuzumab plus CHOP as front-line chemotherapy for patients with peripheral T-cell lymphomas: a phase II study. Cancer Chemotherapy and Pharmacology, 60, 129-134.
145. Kim, S.J., Kim, K., Kim, B.S., Kim, C.Y., Suh, C., Huh, J., Lee, S.W., Kim, J.S., Cho, J., Lee, G.W., Kang, K.M., Eom, H.S., Pyo, H.R., Ahn, Y.C., Ko, Y.H. & Kim, W.S. (2009) Phase II trial of concurrent radiation and weekly cisplatin followed by VIPD chemotherapy in newly diagnosed, stage IE to IIE, nasal, extranodal NK/T-Cell Lymphoma: Consortium for Improving Survival of Lymphoma study. Journal of Clinical Oncology, 27, 6027-6032.
146. Kim, T.M., Lee, S.Y., Jeon, Y.K., Ryoo, B.Y., Cho, G.J., Hong, Y.S., Kim, H.J., Kim, S.Y., Kim, C.S., Kim, S., Kim, J.S., Sohn, S.K., Song, H.H., Lee, J.L., Kang, Y.K., Yim, C.Y., Lee, W.S., Yuh, Y.J., Kim, C.W. & Heo, D.S. (2008) Clinical heterogeneity of extranodal NK/T-cell lymphoma, nasal type: a national survey of the Korean Cancer Study Group. Annals of Oncology, 19, 1477-1484.
147. Kluin- Nelemans, J.C., Kooij Van Marwijk, M., Lugtenburg, P.J., Wijermans, P.W., Van Putten, W.J.L. & van Imhoff, G.W. (2008) Alemtuzumab-CHOP for aggressive T cell lymphoma. A Phase II HOVON 69 Trial. Blood (ASH Annual Meeting Abstracts), 112, 1999.
148. Konuma, T., Ooi, J., Takahashi, S., Tomonari, A., Tsukada, N., Kobayashi, T., Sato, A., Tojo, A. & Asano, S. (2007) Allogeneic stem cell transplantation for hepatosplenic gammadelta T-cell lymphoma. Leukaemia & Lymphoma, 48, 630-632.
149. Krishnan, B., Else, M., Tjonnfjord, G.E., Cazin, B., Carney, D., Carter, J., Ketterer, N., Catovsky, D., Ethell, M., Matutes, E. & Dearden, C.E. (2010) Stem cell transplantation after alemtuzumab in T-cell prolymphocytic leukaemia results in longer survival than after alemtuzumab alone: a multicentre retrospective study. British Journal of Haematology, 149, 907-910.
150. Kwong, Y.L. (2005) Natural killer-cell malignancies: diagnosis and treatment. Leukemia, 19, 2186-2194.
151. Kwong, YL, Chan, AC, Liang, R, Chiang, AK, Chim, CS, Chan, TK, Todd, D & Ho, FC (1997) CD56+ NK lymphomas: clinicopathological features and prognosis. British Journal of Haematology, 97, 821-829.
152. Kyriakou, C., Canals, C., Goldstone, A., Caballero, D., Metzner, B., Kobbe, G., Kolb, H.J., Kienast, J., Reimer, P., Finke, J., Oberg, G., Hunter, A., Theorin, N., Sureda, A. & Schmitz, N. (2008) High-dose therapy and autologous stem-cell transplantation in angioimmunoblastic lymphoma: complete remission at transplantation is the major determinant of Outcome-Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. Journal of Clinical Oncology, 26, 218-224.
153. Lamant, L., de Reynies, A., Duplantier, M.M., Rickman, D.S., Sabourdy, F., Giuriato, S., Brugieres, L., Gaulard, P., Espinos, E. & Delsol, G. (2007) Gene-expression profiling of systemic anaplastic large-cell lymphoma reveals differences based on ALK status and two distinct morphologic ALK+ subtypes. Blood, 109, 2156-2164.
154. Lamy, T., LePrise, P.Y., Amiot, L., Drenou, B., Fauchet, R., Genetet, N. & Semana, G. (1995) Response to granulocyte-macrophage colony-stimulating factor (GM-CSF) but not to G-CSF in a case of agranulocytosis associated with large granular lymphocyte (LGL) leukemia. Blood, 85, 3352-3353.
155. de Lavallade, H., Faucher, C., Furst, S., El-Cheikh, J., Vey, N., Coso, D., Bouabdallah, R., Stoppa, A.M., Gastaut, J.A., Blaise, D. & Mohty, M. (2006) Allogeneic stem cell transplantation after reduced-intensity conditioning in a patient with T-cell prolymphocytic leukemia: graft-versus-tumor effect and long-term remission. Bone Marrow Transplantation, 37, 709-710.
156. Le Deley, M.C., Reiter, A., Williams, D., Delsol, G., Oschlies, I., McCarthy, K., Zimmermann, M. & Brugieres, L. (2008) Prognostic factors in childhood anaplastic large cell lymphoma: results of a large European intergroup study. Blood, 111, 1560-1566.
157. Le Gouill, S., Milpied, N., Buzyn, A., De Latour, R.P., Vernant, J.P., Mohty, M., Moles, M.P., Bouabdallah, K., Bulabois, C.E., Dupuis, J., Rio, B., Gratecos, N., Yakoub-Agha, I., Attal, M., Tournilhac, O., Decaudin, D., Bourhis, J.H., Blaise, D., Volteau, C. & Michallet, M. (2008) Graft-versus-lymphoma effect for aggressive T-cell lymphomas in adults: a study by the Societe Francaise de Greffe de Moelle et de Therapie Cellulaire. Journal of Clinical Oncology, 26, 2264-2271.
158. Lee, J., Suh, C., Park, Y.H., Ko, Y.H., Bang, S.M., Lee, J.H., Lee, D.H., Huh, J., Oh, S.Y., Kwon, H.C., Kim, H.J., Lee, S.I., Kim, J.H., Park, J., Oh, S.J., Kim, K., Jung, C., Park, K. & Kim, W.S. (2006) Extranodal natural killer T-cell lymphoma, nasal-type: a prognostic model from a retrospective multicenter study. Journal of Clinical Oncology, 24, 612-618.
159. de Leval, L., Rickman, D.S., Thielen, C., Reynies, A., Huang, Y.L., Delsol, G., Lamant, L., Leroy, K., Briere, J., Molina, T., Berger, F., Gisselbrecht, C., Xerri, L. & Gaulard, P. (2007) The gene expression profile of nodal peripheral T-cell lymphoma demonstrates a molecular link between angioimmunoblastic T-cell lymphoma (AITL) and follicular helper T (TFH) cells. Blood, 109, 4952-4963.
160. Li, Y.X., Yao, B., Jin, J., Wang, W.H., Liu, Y.P., Song, Y.W., Wang, S.L., Liu, X.F., Zhou, L.Q., He, X.H., Lu, N. & Yu, Z.H. (2006) Radiotherapy as primary treatment for stage IE and IIE nasal natural killer/T-cell lymphoma. Journal of Clinical Oncology, 24, 181-189.
161. Li, Y.X., Liu, Q.F., Fang, H., Qi, S.N., Wang, H., Wang, W.H., Song, Y.W., Lu, J., Jin, J., Wang, S.L., Liu, Y.P., Lu, N., Liu, X.F. & Yu, Z.H. (2009) Variable clinical presentations of nasal and Waldeyer ring natural killer/T-cell lymphoma. Clinical Cancer Research, 15, 2905-2912.
162. Linden, O. (2004) Remission of a refractory, anaplastic large-cell lymphoma after treatment with daclizumab. New England Journal of Medicine, 351, 1466-1467.
163. Lopez-Guillermo, A., Cid, J., Salar, A., Lopez, A., Montalban, C., Castrillo, J.M., Gonzalez, M., Ribera, J.M., Brunet, S., Garcia-Conde, J., Fernandez de Sevilla, A., Bosch, F. & Montserrat, E. (1998) Peripheral T-cell lymphomas: initial features, natural history, and prognostic factors in a series of 174 patients diagnosed according to the R.E.A.L. Classification. Annals of Oncology, 9, 849-855.
164. Loughran, Jr, T.P., Starkebaum, G., Clark, E., Wallace, P. & Kadin, M.E. (1987) Evaluation of splenectomy in large granular lymphocyte leukaemia. British Journal of Haematology, 67, 135-140.
165. Loughran, Jr, T.P., Kidd, P.G. & Starkebaum, G. (1994) Treatment of large granular lymphocyte leukemia with oral low-dose methotrexate. Blood, 84, 2164-2170.
166. Lundin, J., Osterborg, A., Brittinger, G., Crowther, D., Dombret, H., Engert, A., Epenetos, A., Gisselbrecht, C., Huhn, D., Jaeger, U., Thomas, J., Marcus, R., Nissen, N., Poynton, C., Rankin, E., Stahel, R., Uppenkamp, M., Willemze, R. & Mellstedt, H. (1998) CAMPATH-1H monoclonal antibody in therapy for previously treated low-grade non-Hodgkin's lymphomas: a phase II multicenter study. European Study Group of CAMPATH-1H Treatment in Low-Grade Non-Hodgkin's Lymphoma. Journal of Clinical Oncology, 16, 3257-3263.
167. Macon, W.R., Levy, N.B., Kurtin, P.J., Salhany, K.E., Elkhalifa, M.Y., Casey, T.T., Craig, F.E., Vnencak- Jones, C.L., Gulley, M.L., Park, J.P. & Cousar, J.B. (2001) Hepatosplenic alphabeta T-cell lymphomas: a report of 14 cases and comparison with hepatosplenic gammadelta T-cell lymphomas. American Journal of Surgical Pathology, 25, 285-296.
168. Madani, A., Choukroun, V., Soulier, J., Cacheux, V., Claisse, J.F., Valensi, F., Daliphard, S., Cazin, B., Levy, V., Leblond, V., Daniel, M.T., Sigaux, F. & Stern, M.H. (1996) Expression of p13MTCP1 is restricted to mature T-cell proliferations with t(X;14) translocations. Blood, 87, 1923-1927.
169. Mallant, M., Hadithi, M., Al- Toma, A.B., Kater, M., Jacobs, M., Manoliu, R., Mulder, C. & van Waesberghe, J.H. (2007) Abdominal computed tomography in refractory coeliac disease and enteropathy associated T-cell lymphoma. World Journal of Gastroenterology, 13, 1696-1700.
170. Man, C., Au, W.Y., Pang, A. & Kwong, Y.L. (2002) Deletion 6q as a recurrent chromosomal aberration in T-cell large granular lymphocyte leukemia. Cancer Genetics and Cytogenetics, 139, 71-74.
171. Marchi, E., Alinari, L., Tani, M., Stefoni, V., Pimpinelli, N., Berti, E., Pagano, L., Bernengo, M.G., Zaja, F., Rupoli, S., Pileri, S., Baccarani, M. & Zinzani, P.L. (2005) Gemcitabine as frontline treatment for cutaneous T-cell lymphoma: phase II study of 32 patients. Cancer, 104, 2437-2441.
172. Martinez-Delgado, B., Cuadros, M., Honrado, E., Ruiz de la Parte, A., Roncador, G., Alves, J., Castrillo, J.M., Rivas, C. & Benitez, J. (2005) Differential expression of NF-kappaB pathway genes among peripheral T-cell lymphomas. Leukemia, 19, 2254-2263.
173. Massone, C., Chott, A., Metze, D., Kerl, K., Citarella, L., Vale, E., Kerl, H. & Cerroni, L. (2004) Subcutaneous, blastic natural killer (NK), NK/T-cell, and other cytotoxic lymphomas of the skin: a morphologic, immunophenotypic, and molecular study of 50 patients. American Journal of Surgical Pathology, 28, 719-735.
174. Matsue, K., Fujiwara, H. & Sandoh, E. (2009) (18)F-Fluorodeoxyglucose positron emission tomography in primary cutaneous NK/T cell lymphoma, nasal type. European Journal of Haematology, 82, 493-494.
175. Matsuoka, M. & Jeang, K.T. (2007) Human T-cell leukaemia virus type 1 (HTLV-1) infectivity and cellular transformation. Nature Reviews Cancer, 7, 270-280.
176. Matsushita, K., Matsumoto, T., Ohtsubo, H., Fujiwara, H., Imamura, N., Hidaka, S., Kukita, T., Tei, C., Matsumoto, M. & Arima, N. (1999) Long-term maintenance combination chemotherapy with OPEC/MPEC (vincristine or methotrexate, prednisolone, etoposide and cyclophosphamide) or with daily oral etoposide and prednisolone can improve survival and quality of life in adult T-cell leukemia/lymphoma. Leukaemia & Lymphoma, 36, 67-75.
177. Matutes, E., Brito-Babapulle, V., Swansbury, J., Ellis, J., Morilla, R., Dearden, C., Sempere, A. & Catovsky, D. (1991) Clinical and laboratory features of 78 cases of T-prolymphocytic leukemia. Blood, 78, 3269-3274.
178. Matutes, E., Wotherspoon, A.C., Parker, N.E., Osuji, N., Isaacson, P.G. & Catovsky, D. (2001a) Transformation of T-cell large granular lymphocyte leukaemia into a high-grade large T-cell lymphoma. British Journal of Haematology, 115, 801-806.
179. Matutes, E., Taylor, G.P., Cavenagh, J., Pagliuca, A., Bareford, D., Domingo, A., Hamblin, M., Kelsey, S., Mir, N. & Reilly, J.T. (2001b) Interferon alpha and zidovudine therapy in adult T-cell leukaemia lymphoma: response and outcome in 15 patients. British Journal of Haematology, 113, 779-784.
180. McMillan, A. (2005) Central nervous system-directed preventative therapy in adults with lymphoma. British Journal of Haematology, 131, 13-21.
181. Melnyk, A., Rodriguez, A., Pugh, W.C. & Cabannillas, F. (1997) Evaluation of the Revised European-American Lymphoma classification confirms the clinical relevance of immunophenotype in 560 cases of aggressive non-Hodgkin's lymphoma. Blood, 89, 4514-4520.
182. Mercadal, S., Briones, J., Xicoy, B., Pedro, C., Escoda, L., Estany, C., Camos, M., Colomo, L., Espinosa, I., Martinez, S., Ribera, J.M., Martino, R., Gutierrez-Garcia, G., Montserrat, E. & Lopez-Guillermo, A. (2008) Intensive chemotherapy (high-dose CHOP/ESHAP regimen) followed by autologous stem-cell transplantation in previously untreated patients with peripheral T-cell lymphoma. Annals of Oncology, 19, 958-963.
183. Mercieca, J., Matutes, E., Dearden, C., MacLennan, K. & Catovsky, D. (1994) The role of pentostatin in the treatment of T-cell malignancies: analysis of response rate in 145 patients according to disease subtype. Journal of Clinical Oncology, 12, 2588-2593.
184. Mittal, S., Milner, B.J., Johnston, P.W. & Culligan, D.J. (2006) A case of hepatosplenic gamma-delta T-cell lymphoma with a transient response to fludarabine and alemtuzumab. European Journal of Haematology, 76, 531-534.
185. Miyazato, H., Nakatsuka, S., Dong, Z., Takakuwa, T., Oka, K., Hanamoto, H., Tatsumi, Y., Kanamaru, A. & Aozasa, K. (2004) NK-cell related neoplasms in Osaka, Japan. American Journal of Hematology, 76, 230-235.
186. Mohan, S.R., Clemente, M., Wlodarski, M., Lichtin, A.E. & Maciejewski, J.P. (2008) Alemtuzumab shows significant efficacy in T-LGL leukemia and refractory cases are due to GPI-deficiency of LGL clones. Blood (ASH Annual Meeting Abstracts), 112, 2038.
187. Mone, A., Puhalla, S., Whitman, S., Baiocchi, R.A., Cruz, J., Vukosavljevic, T., Banks, A., Eisenbeis, C.F., Byrd, J.C., Caligiuri, M.A. & Porcu, P. (2005) Durable hematologic complete response and suppression of HTLV-1 viral load following alemtuzumab in zidovudine/IFN-{alpha}-refractory adult T-cell leukemia. Blood, 106, 3380-3382.
188. Mounier, N., Gisselbrecht, C., Briere, J., Haioun, C., Feugier, P., Offner, F., Recher, C., Stamatoullas, A., Morschhauser, F., Macro, M., Thieblemont, C., Sonet, A., Fabiani, B. & Reyes, F. (2004) Prognostic factors in patients with aggressive non-Hodgkin's lymphoma treated by front-line autotransplantation after complete remission: a cohort study by the Groupe d'Etude des Lymphomes de l'Adulte. Journal of Clinical Oncology, 22, 2826-2834.
189. Moura, I.C., Lepelletier, Y., Arnulf, B., England, P., Baude, C., Beaumont, C., Bazarbachi, A., Benhamou, M., Monteiro, R.C. & Hermine, O. (2004) A neutralizing monoclonal antibody (mAb A24) directed against the transferrin receptor induces apoptosis of tumor T lymphocytes from ATL patients. Blood, 103, 1838-1845.
190. Mourad, N., Mounier, N., Briere, J., Raffoux, E., Delmer, A., Feller, A., Meijer, C.J., Emile, J.F., Bouabdallah, R., Bosly, A., Diebold, J., Haioun, C., Coiffier, B., Gisselbrecht, C. & Gaulard, P. (2008) Clinical, biologic, and pathologic features in 157 patients with angioimmunoblastic T-cell lymphoma treated within the Groupe d'Etude des Lymphomes de l'Adulte (GELA) trials. Blood, 111, 4463-4470.
191. Murayama, T., Imoto, S., Takahashi, T., Ito, M., Matozaki, S. & Nakagawa, T. (1992) Successful treatment of angioimmunoblastic lymphadenopathy with dysproteinemia with cyclosporin A. Cancer, 69, 2567-2570.
192. Nakase, K., Hara, M., Kozuka, T., Tanimoto, K. & Nawa, Y. (2006) Bone marrow transplantation from unrelated donors for patients with adult T-cell leukaemia/lymphoma. Bone Marrow Transplantation, 37, 41-44.
193. Nakashima, Y., Tagawa, H., Suzuki, R., Karnan, S., Karube, K., Ohshima, K., Muta, K., Nawata, H., Morishima, Y., Nakamura, S. & Seto, M. (2005) Genome-wide array-based comparative genomic hybridization of natural killer cell lymphoma/leukemia: different genomic alteration patterns of aggressive NK-cell leukemia and extranodal Nk/T-cell lymphoma, nasal type. Genes Chromosomes Cancer, 44, 247-255.
194. Nascimento, A.F., Pinkus, J.L. & Pinkus, G.S. (2004) Clusterin, a marker for anaplastic large cell lymphoma immunohistochemical profile in hematopoietic and nonhematopoietic malignant neoplasms. American Journal of Clinical Pathology, 121, 709-717.
195. Nasr, R., El- Sabban, M.E., Karam, J.A., Dbaibo, G., Kfoury, Y., Arnulf, B., Lepelletier, Y., Bex, F., de The, H., Hermine, O. & Bazarbachi, A. (2005) Efficacy and mechanism of action of the proteasome inhibitor PS-341 in T-cell lymphomas and HTLV-I associated adult T-cell leukemia/lymphoma. Oncogene, 24, 419-430.
196. Nelson, M., Horsman, D.E., Weisenburger, D.D., Gascoyne, R.D., Dave, B.J., Loberiza, F.R., Ludkovski, O., Savage, K.J., Armitage, J.O. & Sanger, W.G. (2008) Cytogenetic abnormalities and clinical correlations in peripheral T-cell lymphoma. British Journal of Haematology, 141, 461-469.
197. Nowakowski, G.S., Morice, W.G., Zent, C.S., Schwager, S.M., Li, C., Markovic, S.N., Porrata, L., Tefferi, A. & Phyliky, R.L. (2006) Initial presentation and prognostic factors in 286 patients with T-cell large granular lymphocyte leukemia. Blood (ASH Annual Meeting Abstracts), 108, 300.
198. Obama, K., Tara, M. & Niina, K. (2003) L-asparaginase-Based induction therapy for advanced extranodal NK/T-cell lymphoma. International Journal of Hematology, 78, 248-250.
199. O'Connor, O.A., Hamlin, P.A., Portlock, C., Moskowitz, C.H., Noy, A., Straus, D.J., Macgregor-Cortelli, B., Neylon, E., Sarasohn, D., Dumetrescu, O., Mould, D.R., Fleischer, M., Zelenetz, A.D., Sirotnak, F. & Horwitz, S. (2007) Pralatrexate, a novel class of antifol with high affinity for the reduced folate carrier-type 1, produces marked complete and durable remissions in a diversity of chemotherapy refractory cases of T-cell lymphoma. British Journal of Haematology, 139, 425-428.
200. O'Connor, O.A., Pro, B., Pinter-Brown, L., Popplewell, L., Barlett, N., Shustov, A., Lechowicz, M.J., Savage, K.J., Coiffier, B., Jacobsen, E., Zinzani, P.L., Goy, A., Zain, J., Wilroy, S., Patterson, M., Boyd, A., Saunders, M.E., Cagnoni, P. & Horwitz, S.M. (2008) PROPEL: a multi-center phase 2 open-label study of pralatrexate (PDX) with vitamin B12 and folic acid supplementation in patients with relapsed or refractory peripheral T-cell lymphoma. Blood (ASH Annual Meeting Abstracts), 112, 261.
201. O'Connor, O.A., Horwitz, S., Hamlin, P., Portlock, C., Moskowitz, C.H., Sarasohn, D., Neylon, E., Mastrella, J., Hamelers, R., Macgregor-Cortelli, B., Patterson, M., Seshan, V.E., Sirotnak, F., Fleisher, M., Mould, D.R., Saunders, M. & Zelenetz, A.D. (2009) Phase II-I-II study of two different doses and schedules of pralatrexate, a high-affinity substrate for the reduced folate carrier, in patients with relapsed or refractory lymphoma reveals marked activity in T-cell malignancies. Journal of Clinical Oncology, 27, 4357-4364.
202. Ohsaka, A., Saito, K., Sakai, T., Mori, S., Kobayashi, Y., Amemiya, Y., Sakamoto, S. & Miura, Y. (1992) Clinicopathologic and therapeutic aspects of angioimmunoblastic lymphadenopathy-related lesions. Cancer, 69, 1259-1267.
203. Okamura, J., Utsunomiya, A., Tanosaki, R., Uike, N., Sonoda, S., Kannagi, M., Tomonaga, M., Harada, M., Kimura, N., Masuda, M., Kawano, F., Yufu, Y., Hattori, H., Kikuchi, H. & Saburi, Y. (2005) Allogeneic stem-cell transplantation with reduced conditioning intensity as a novel immunotherapy and antiviral therapy for adult T-cell leukemia/lymphoma. Blood, 105, 4143-4145.
204. Ong, S.T., Koeppen, H., Larson, R.A. & Olopade, O.I. (1996) Successful treatment of angioimmunoblastic lymphadenopathy with dysproteinemia with fludarabine. Blood, 88, 2354-2355.
205. Oshimi, K. (2007) Progress in understanding and managing natural killer-cell malignancies. British Journal of Haematology, 139, 532-544.
206. Osuji, N., Matutes, E., Tjonnfjord, G., Grech, H., Del Giudice, I., Wotherspoon, A., Swansbury, J.G. & Catovsky, D. (2006) T-cell large granular lymphocyte leukemia: a report on the treatment of 29 patients and a review of the literature. Cancer, 107, 570-578.
207. Papenfuss, J.S., Aoun, P., Bierman, P.J. & Armitage, J.O. (2002) Subcutaneous panniculitis-like T-cell lymphoma: presentation of 2 cases and observations. Clinical Lymphoma, 3, 175-180.
208. Passoni, L. & Gambacorti-Passerini, C. (2003) ALK a novel lymphoma-associated tumor antigen for vaccination strategies. Leukaemia & Lymphoma, 44, 1675-1681.
209. Pautier, P., Devidas, A., Delmer, A., Dombret, H., Sutton, L., Zini, J.M., Nedelec, G., Molina, T., Marolleau, J.P. & Brice, P. (1999) Angioimmunoblastic-like T-cell non Hodgkin's lymphoma: outcome after chemotherapy in 33 patients and review of the literature. Leukaemia & Lymphoma, 32, 545-552.
210. Pellatt, J., Sweetenham, J., Pickering, R.M., Brown, L. & Wilkins, B. (2002) A single-centre study of treatment outcomes and survival in 120 patients with peripheral T-cell non-Hodgkin's lymphoma. Annals of Hematology, 81, 267-272.
211. Piccaluga, P.P., Agostinelli, C., Califano, A., Rossi, M., Basso, K., Zupo, S., Went, P., Klein, U., Zinzani, P.L., Baccarani, M., Dalla Favera, R. & Pileri, S.A. (2007a) Gene expression analysis of peripheral T cell lymphoma, unspecified, reveals distinct profiles and new potential therapeutic targets. Journal of Clinical Investigation, 117, 823-834.
212. Piccaluga, P.P., Agostinelli, C., Righi, S., Zinzani, P.L. & Pileri, S.A. (2007b) Expression of CD52 in peripheral T-cell lymphoma. Haematologica, 92, 566-567.
213. Piekarz, R.L., Robey, R.W., Zhan, Z., Kayastha, G., Sayah, A., Abdeldaim, A.H., Torrico, S. & Bates, S.E. (2011) T-cell lymphoma as a model for the use of histone deacetylase inhibitors in cancer therapy: impact of depsipeptide on molecular markers, therapeutic targets, and mechanisms of resistance. Blood, 103, 4636-4643.
214. Pieters, R., Martens, J. & Dequeker, J. (1982) Rheumatoid arthritis associated with bronchiolitis obliterans and immunoblastic sarcoma. Clinical Rheumatology, 1, 35-40.
215. Pise-Masison, C.A., Radonovich, M., Dohoney, K., Morris, J.C., O'Mahony, D., Lee, M.J., Trepel, J., Waldmann, T.A., Janik, J.E. & Brady, J.N. (2009) Gene expression profiling of ATL patients: compilation of disease-related genes and evidence for TCF4 involvement in BIRC5 gene expression and cell viability. Blood, 113, 4016-4026.
216. Piva, R., Chiarle, R., Manazza, A.D., Taulli, R., Simmons, W., Ambrogio, C., D'Escamard, V., Pellegrino, E., Ponzetto, C., Palestro, G. & Inghirami, G. (2006) Ablation of oncogenic ALK is a viable therapeutic approach for anaplastic large-cell lymphomas. Blood, 107, 689-697.
217. Piva, R., Agnelli, L., Pellegrino, E., Todoerti, K., Grosso, V., Tamagno, I., Fornari, A., Martinoglio, B., Medico, E., Zamo, A., Facchetti, F., Ponzoni, M., Geissinger, E., Rosenwald, A., Muller- Hermelink, H.K., De Wolf-Peeters, C., Piccaluga, P.P., Pileri, S., Neri, A. & Inghirami, G. (2010) Gene expression profiling uncovers molecular classifiers for the recognition of anaplastic large-cell lymphoma within peripheral T-cell neoplasms. Journal of Clinical Oncology, 28, 1583-1590.
218. Proietti, F.A., Carneiro- Proietti, A.B., Catalan- Soares, B.C. & Murphy, E.L. (2005) Global epidemiology of HTLV-1 infection and associated diseases. Oncogene, 24, 6058-6068.
219. Pulford, K., Morris, S.W. & Mason, D.Y. (2001) Anaplastic lymphoma kinase proteins and malignancy. Current Opinion in Hematology, 8, 231-236.
220. Ramos, J.C., Ruiz, Jr, P., Ratner, L., Reis, I.M., Brites, C., Pedroso, C., Byrne, Jr, G.E., Toomey, N.L., Andela, V., Harhaj, E.W., Lossos, I.S. & Harrington, Jr, W.J. (2007) IRF-4 and c-Rel expression in antiviral-resistant adult T-cell leukemia/lymphoma. Blood, 109, 3060-3068.
221. Ratner, L., Grant, C., Zimmerman, B., Fritz, J., Weil, G., Denes, A., Suresh, R., Campbell, N., Jacobson, S. & Lairmore, M. (2007) Effect of treatment of Strongyloides infection on HTLV-1 expression in a patient with adult T-cell leukemia. American Journal of Hematology, 82, 929-931.
222. Ravandi, F. & Faderl, S. (2006) Complete response in a patient with adult T-cell leukemia (ATL) treated with combination of alemtuzumab and pentostatin. Leukemia Research, 30, 103-105.
223. Ravandi, F., Aribi, A., O'Brien, S., Faderl, S., Jones, D., Ferrajoli, A., Huang, X., York, S., Pierce, S., Wierda, W., Kontoyiannis, D., Verstovsek, S., Pro, B., Fayad, L., Keating, M. & Kantarjian, H. (2009) Phase II study of alemtuzumab in combination with pentostatin in patients with T-cell neoplasms. Journal of Clinical Oncology, 27, 5425-5430.
224. Reimer, P., Rudiger, T., Geissinger, E., Weissinger, F., Nerl, C., Schmitz, N., Engert, A., Einsele, H., Muller- Hermelink, H.K. & Wilhelm, M. (2009) Autologous stem-cell transplantation as first-line therapy in peripheral T-cell lymphomas: results of a prospective multicenter study. Journal of Clinical Oncology, 27, 106-113.
225. Rodig, S.J., Abramson, J.S., Pinkus, G.S., Treon, S.P., Dorfman, D.M., Dong, H.Y., Shipp, M.A. & Kutok, J.L. (2006) Heterogeneous CD52 expression among hematologic neoplasms: implications for the use of alemtuzumab (CAMPATH-1H). Clinical Cancer Research, 12, 7174-7179.
226. Rodriguez, J., Conde, E., Gutierrez, A., Arranz, R., Leon, A., Marin, J., Bendandi, M., Albo, C. & Caballero, M.D. (2007a) The results of consolidation with autologous stem-cell transplantation in patients with peripheral T-cell lymphoma (PTCL) in first complete remission: the Spanish Lymphoma and Autologous Transplantation Group experience. Annals of Oncology, 18, 652-657.
227. Rodriguez, J., Conde, E., Gutierrez, A., Arranz, R., Leon, A., Marin, J., Bendandi, M., Albo, C. & Caballero, M.D. (2007b) Frontline autologous stem cell transplantation in high-risk peripheral T-cell lymphoma: a prospective study from The Gel-Tamo Study Group. European Journal of Haematology, 79, 32-38.
228. Rodriguez, J., Conde, E., Gutierrez, A., Arranz, R., Gandarillas, M., Leon, A., Ojanguren, J., Sureda, A., Carrera, D., Bendandi, M., Moraleda, J., Ribera, J.M., Albo, C., Morales, A., Garcia, J.C., Fernandez, P., Canigral, G., Bergua, J. & Caballero, M.D. (2007c) Prolonged survival of patients with angioimmunoblastic T-cell lymphoma after high-dose chemotherapy and autologous stem cell transplantation: the GELTAMO experience. European Journal of Haematology, 78, 290-296.
229. Rosenblum, M.D., LaBelle, J.L., Chang, C.C., Margolis, D.A., Schauer, D.W. & Vesole, D.H. (2004) Efficacy of alemtuzumab treatment for refractory T-cell large granular lymphocytic leukemia. Blood, 103, 1969-1971.
230. Ru, X. & Liebman, H.A. (2003) Successful treatment of refractory pure red cell aplasia associated with lymphoproliferative disorders with the anti-CD52 monoclonal antibody alemtuzumab (Campath-1H). British Journal of Haematology, 123, 278-281.
231. Rüdiger, T., Weisenburger, D.D., Anderson, J.R., Armitage, J.O., Diebold, J., MacLennan, K.A., Nathwani, B.N., Ullrich, F. & Muller- Hermelink, H.K. (2002) Peripheral T-cell lymphoma (excluding anaplastic large-cell lymphoma): results from the Non-Hodgkin's Lymphoma Classification Project. Annals of Oncology, 13, 140-149.
232. Rüdiger, T., Coiffier, B., Weisenburger, D.D. & Federico, M. (2006) International T-Cell Lymphoma Classification Project: Angioimmunoblastic T-Cell Lymphoma. ASH Annual Meeting Abstracts, 108, 2052.
233. Sakai, R., Fujisawa, S., Fujimaki, K., Kanamori, H. & Ishigatsubo, Y. (2006) Long-term remission in a patient with hepatosplenic gammadelta T cell lymphoma after cord blood stem cell transplantation following autologous peripheral blood stem cell transplantation. Bone Marrow Transplantation, 37, 537-538.
234. Salaverria, I., Bea, S., Lopez-Guillermo, A., Lespinet, V., Pinyol, M., Burkhardt, B., Lamant, L., Zettl, A., Horsman, D., Gascoyne, R., Ott, G., Siebert, R., Delsol, G. & Campo, E. (2008) Genomic profiling reveals different genetic aberrations in systemic ALK-positive and ALK-negative anaplastic large cell lymphomas. British Journal of Haematology, 140, 516-526.
235. Salhany, K.E., Macon, W.R., Choi, J.K., Elenitsas, R., Lessin, S.R., Felgar, R.E., Wilson, D.M., Przybylski, G.K., Lister, J., Wasik, M.A. & Swerdlow, S.H. (1998) Subcutaneous panniculitis-like T-cell lymphoma: clinicopathologic, immunophenotypic, and genotypic analysis of alpha/beta and gamma/delta subtypes. American Journal of Surgical Pathology, 22, 881-893.
236. Sallah, S., Wehbie, R., Lepera, P., Sallah, W. & Bobzien, W. (1999) The role of 2-chlorodeoxyadenosine in the treatment of patients with refractory angioimmunoblastic lymphadenopathy with dysproteinemia. British Journal of Haematology, 104, 163-165.
237. Sallah, S., Wan, J.Y. & Nguyen, N.P. (2001) Treatment of refractory T-cell malignancies using gemcitabine. British Journal of Haematology, 113, 185-187.
238. Sasaki, H., Nishikata, I., Shiraga, T., Akamatsu, E., Fukami, T., Hidaka, T., Kubuki, Y., Okayama, A., Hamada, K., Okabe, H., Murakami, Y., Tsubouchi, H. & Morishita, K. (2005) Overexpression of a cell adhesion molecule, TSLC1, as a possible molecular marker for acute-type adult T-cell leukemia. Blood, 105, 1204-1213.
239. Savage, K.J., Chhanabhai, M., Gascoyne, R.D. & Connors, J.M. (2004) Characterization of peripheral T-cell lymphomas in a single North American institution by the WHO classification. Annals of Oncology, 15, 1467-1475.
240. Savage, K.J., Harris, N.L., Vose, J.M., Ullrich, F., Jaffe, E.S., Connors, J.M., Rimsza, L., Pileri, S.A., Chhanabhai, M., Gascoyne, R.D., Armitage, J.O. & Weisenburger, D.D. (2008) ALK- anaplastic large-cell lymphoma is clinically and immunophenotypically different from both ALK+ ALCL and peripheral T-cell lymphoma, not otherwise specified: report from the International Peripheral T-Cell Lymphoma Project. Blood, 111, 5496-5504.
241. Schetelig, J., Fetscher, S., Reichle, A., Berdel, W.E., Beguin, Y., Brunet, S., Caballero, D., Majolino, I., Hagberg, H., Johnsen, H.E., Kimby, E., Montserrat, E., Stewart, D., Copplestone, A., Rosler, W., Pavel, J., Kingreen, D. & Siegert, W. (2003) Long-term disease-free survival in patients with angioimmunoblastic T-cell lymphoma after high-dose chemotherapy and autologous stem cell transplantation. Haematologica, 88, 1272-1278.
242. Schlegelberger, B., Zwingers, T., Hohenadel, K., Henne-Bruns, D., Schmitz, N., Haferlach, T., Tirier, C., Bartels, H., Sonnen, R., Kuse, R. (1996) Significance of cytogenetic findings for the clinical outcome in patients with T-cell lymphoma of angioimmunoblastic lymphadenopathy type. Journal of Clinical Oncology, 14, 593-599.
243. Schlette, E.J., Medeiros, L.J., Goy, A., Lai, R. & Rassidakis, G.Z. (2004) Survivin expression predicts poorer prognosis in anaplastic large-cell lymphoma. Journal of Clinical Oncology, 22, 1682-1688.
244. Schmitz, N., Trumper, L., Ziepert, M., Nickelsen, M., Ho, A.D., Metzner, B., Peter, N., Loeffler, M., Rosenwald, A. & Pfreundschuh, M. (2010) Treatment and prognosis of mature T-cell and NK-cell lymphoma: an analysis of patients with T-cell lymphoma treated in studies of the German High-Grade Non-Hodgkin Lymphoma Study Group. Blood, 116, 3418-3425.
245. Schwarzmeier, J.D., Reinisch, W.W., Kurkciyan, I.E., Gasche, C.W., Dittrich, C., Ihra, G.C. & Augustin, I. (1991) Interferon-alpha induces complete remission in angioimmunoblastic lymphadenopathy (AILD): late development of aplastic anaemia with cytokine abnormalities. British Journal of Haematology, 79, 336-337.
246. Seehafer, J.R., Goldberg, N.C., Dicken, C.H. & Su, W.P. (1980) Cutaneous manifestations of angioimmunoblastic lymphadenopathy. Archives of Dermatology, 116, 41-45.
247. Seidemann, K., Tiemann, M., Schrappe, M., Yakisan, E., Simonitsch, I., Janka-Schaub, G., Dorffel, W., Zimmermann, M., Mann, G., Gadner, H., Parwaresch, R., Riehm, H. & Reiter, A. (2001) Short-pulse B-non-Hodgkin lymphoma-type chemotherapy is efficacious treatment for pediatric anaplastic large cell lymphoma: a report of the Berlin-Frankfurt-Munster Group Trial NHL-BFM 90. Blood, 97, 3699-3706.
248. Semenzato, G., Zambello, R., Starkebaum, G., Oshimi, K. & Loughran, Jr, T.P. (1997) The lymphoproliferative disease of granular lymphocytes: updated criteria for diagnosis. Blood, 89, 256-260.
249. Shapiro, M., Wasik, M.A., Junkins- Hopkins, J.M., Rook, A.H., Vittorio, C.C., Itakura, H., Frankel, M.C., Georgala, S. & Schuster, S.J. (2003) Complete remission in advanced blastic NK-cell lymphoma/leukemia in elderly patients using the hyper-CVAD regimen. American Journal of Hematology, 74, 46-51.
250. Sharma, K., Janik, J.E., O'Mahony, D., Stewart, D., Pittaluga, S., Stetler-Stevenson, M., Elaine Jaffe ES, S., Raffeld, M., Fleisher, T.A., Lee, C.C., Urquhart, N., Steinberg, S., Waldmann, T.A. & Morris, J.C. (2008) Alemtuzumab (Campath 1-H) in patients with HTLV-1 associated adult T-cell leukemia/lymphoma. Blood (ASH Annual Meeting Abstracts), 112, 2010.
251. Shimoyama, M. (1991) Diagnostic criteria and classification of clinical subtypes of adult T-cell leukaemia-lymphoma. A report from the Lymphoma Study Group (1984-87). British Journal of Haematology, 79, 428-437.
252. Shimoyama, M. (1992) Treatment of patients with adult T-cell leuemia-lymphoma: an overview. In: Advances in Adult T-Cell Leukemia and HTLV-1 Research (ed. by K. Takatsuki, Y. Hinuma & M. Yoshida ), pp. 43-56. Japan Scientific Societies Press, Tokyo.
253. Shvidel, L., Shtalrid, M., Klepfish, A., Haran, M. & Berrebi, A. (2000) Successful autologous stem cell transplantation in aggressive prolymphocytic leukemia. American Journal of Hematology, 63, 230-231.
254. Siegert, W., Nerl, C., Meuthen, I., Zahn, T., Brack, N., Lennert, K. & Huhn, D. (1991) Recombinant human interferon-alpha in the treatment of angioimmunoblastic lymphadenopathy: results in 12 patients. Leukemia, 5, 892-895.
255. Siegert, W., Agthe, A., Griesser, H., Schwerdtfeger, R., Brittinger, G., Engelhard, M., Kuse, R., Tiemann, M., Lennert, K. & Huhn, D. (1992) Treatment of angioimmunoblastic lymphadenopathy (AILD)-type T-cell lymphoma using prednisone with or without the COPBLAM/IMVP-16 regimen. A multicenter study. Kiel Lymphoma Study Group. Annals of Internal Medicine, 117, 364-370.
256. Siegert, W., Nerl, C., Agthe, A., Engelhard, M., Brittinger, G., Tiemann, M., Lennert, K. & Huhn, D. (1995) Angioimmunoblastic lymphadenopathy (AILD)-type T-cell lymphoma: prognostic impact of clinical observations and laboratory findings at presentation. The Kiel Lymphoma Study Group. Annals of Oncology, 6, 659-664.
257. Sieniawski, M., Angamuthu, N., Boyd, K., Chasty, R., Davies, J., Forsyth, P., Jack, F., Lyons, S., Mounter, P., Revell, P., Proctor, S.J. & Lennard, A.L. (2010) Evaluation of enteropathy-associated T-cell lymphoma comparing standard therapies with a novel regimen including autologous stem cell transplantation. Blood, 115, 3664-3670.
258. Smith, S.D., Bolwell, B.J., Rybicki, L.A., Brown, S., Dean, R., Kalaycio, M., Sobecks, R., Andresen, S., Hsi, E.D., Pohlman, B. & Sweetenham, J.W. (2007) Autologous hematopoietic stem cell transplantation in peripheral T-cell lymphoma using a uniform high-dose regimen. Bone Marrow Transplantation, 40, 239-243.
259. Sokol, L. & Loughran, Jr, T.P. (2006) Large granular lymphocyte leukemia. Oncologist, 11, 263-273.
260. Song, K.W., Mollee, P., Keating, A. & Crump, M. (2003) Autologous stem cell transplant for relapsed and refractory peripheral T-cell lymphoma: variable outcome according to pathological subtype. British Journal of Haematology, 120, 978-985.
261. Sonnen, R., Schmidt, W.P., Muller- Hermelink, H.K. & Schmitz, N. (2005) The International Prognostic Index determines the outcome of patients with nodal mature T-cell lymphomas. British Journal of Haematology, 129, 366-372.
262. Sood, R., Stewart, C.C., Aplan, P.D., Murai, H., Ward, P., Barcos, M. & Baer, M.R. (1998) Neutropenia associated with T-cell large granular lymphocyte leukemia: long-term response to cyclosporine therapy despite persistence of abnormal cells. Blood, 91, 3372-3378.
263. Soulier, J., Pierron, G., Vecchione, D., Garand, R., Brizard, F., Sigaux, F., Stern, M.H. & Aurias, A. (2001) A complex pattern of recurrent chromosomal losses and gains in T-cell prolymphocytic leukemia. Genes Chromosomes Cancer, 31, 248-254.
264. Spencer, A., Reed, K. & Arthur, C. (2007) Pilot study of an outpatient-based approach for advanced lymphoma using vinorelbine, gemcitabine and filgrastim. Internal Medicine Journal, 37, 760-766.
265. Stein, H., Foss, H.D., Durkop, H., Marafioti, T., Delsol, G., Pulford, K., Pileri, S. & Falini, B. (2000) CD30(+) anaplastic large cell lymphoma: a review of its histopathologic, genetic, and clinical features. Blood, 96, 3681-3695.
266. Sternberg, A., Eagleton, H., Pillai, N., Leyden, K., Turner, S., Pearson, D., Littlewood, T. & Hatton, C. (2003) Neutropenia and anaemia associated with T-cell large granular lymphocyte leukaemia responds to fludarabine with minimal toxicity. British Journal of Haematology, 120, 699-701.
267. Stock, W., La, M., Sanford, B., Bloomfield, C.D., Vardiman, J.W., Gaynon, P., Larson, R.A. & Nachman, J. (2008) What determines the outcomes for adolescents and young adults with acute lymphoblastic leukemia treated on cooperative group protocols? A comparison of Children's Cancer Group and Cancer and Leukemia Group B studies. Blood, 112, 1646-1654.
268. Stoppa-Lyonnet, D., Soulier, J., Lauge, A., Dastot, H., Garand, R., Sigaux, F. & Stern, M.H. (1998) Inactivation of the ATM gene in T-cell prolymphocytic leukemias. Blood, 91, 3920-3926.
269. Strupp, C., Aivado, M., Germing, U., Gattermann, N. & Haas, R. (2002) Angioimmunoblastic lymphadenopathy (AILD) may respond to thalidomide treatment: two case reports. Leukaemia & Lymphoma, 43, 133-137.
270. Sugaya, M., Nakamura, K., Asahina, A. & Tamaki, K. (2001) Leukocytoclastic vasculitis with IgA deposits in angioimmunoblastic T cell lymphoma. Journal of Dermatology, 28, 32-37.
271. Sung, H.J., Kim, S.J., Seo, H.Y., Sul, H.R., Choi, J.G., Choi, I.K., Park, K.H., Oh, S.C., Seo, J.H., Choi, C.W., Kim, B.S., Shin, S.W., Kim, Y.H. & Kim, J.S. (2006) Prospective analysis of treatment outcome and prognostic factors in patients with T-cell lymphomas treated by CEOP-B: single institutional study. British Journal of Haematology, 134, 45-53.
272. Suzuki, R., Kagami, Y., Takeuchi, K., Kami, M., Okamoto, M., Ichinohasama, R., Mori, N., Kojima, M., Yoshino, T., Yamabe, H., Shiota, M., Mori, S., Ogura, M., Hamajima, N., Seto, M., Suchi, T., Morishima, Y. & Nakamura, S. (2000) Prognostic significance of CD56 expression for ALK-positive and ALK-negative anaplastic large-cell lymphoma of T/null cell phenotype. Blood, 96, 2993-3000.
273. Suzuki, R., Suzumiya, J., Nakamura, S., Aoki, S., Notoya, A., Ozaki, S., Gondo, H., Hino, N., Mori, H., Sugimori, H., Kawa, K. & Oshimi, K. (2004) Aggressive natural killer-cell leukemia revisited: large granular lymphocyte leukemia of cytotoxic NK cells. leukemia, 18, 763-770.
274. Suzumiya, J., Ohshima, K., Tamura, K., Karube, K., Uike, N., Tobinai, K., Gascoyne, R.D., Vose, J.M., Armitage, J.O. & Weisenburger, D.D. (2009) The International Prognostic Index predicts outcome in aggressive adult T-cell leukemia/lymphoma: analysis of 126 patients from the International Peripheral T-Cell Lymphoma Project. Annals of Oncology, 20, 715-721.
275. Swerdlow, S.H., Campo, E., Harris, N.L., Jaffe, E.S., Pileri, S.A., Stein, H., Thiele, J. & Vardiman, J.W. (eds) (2008) WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. IARC, Lyon.
276. Taguchi, H., Kinoshita, K.I., Takatsuki, K., Tomonaga, M., Araki, K., Arima, N., Ikeda, S., Uozumi, K., Kohno, H., Kawano, F., Kikuchi, H., Takahashi, H., Tamura, K., Chiyoda, S., Tsuda, H., Nishimura, H., Hosokawa, T., Matsuzaki, H., Momita, S., Yamada, O. & Miyoshi, I. (1996) An intensive chemotherapy of adult T-cell leukemia/lymphoma: CHOP followed by etoposide, vindesine, ranimustine, and mitoxantrone with granulocyte colony-stimulating factor support. Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology, 12, 182-186.
277. Takemori, N., Kodaira, J., Toyoshima, N., Sato, T., Sakurai, H., Akakura, N., Kimura, S. & Katagiri, M. (1999) Successful treatment of immunoblastic lymphadenopathy-like T-cell lymphoma with cyclosporin A. Leukaemia & Lymphoma, 35, 389-395.
278. Talpur, R., Apisarnthanarax, N., Ward, S. & Duvic, M. (2002) Treatment of refractory peripheral T-cell lymphoma with denileukin diftitox (ONTAK). Leukaemia & Lymphoma, 43, 121-126.
279. Tanimoto, T.E., Hirano, A., Nagafuji, K., Yamasaki, S., Hashiguchi, M., Okamura, T., Kamezaki, K., Takase, K., Numata, A., Miyamoto, T., Fukuda, T. & Harada, M. (2005) Mismatched unrelated cord blood transplantation in a patient with T-cell prolymphocytic leukemia. leukemia, 19, 679-681.
280. Tannir, N., Riggs, S., Velasquez, W., Samaan, N. & Manning, J. (1985) Hypercalcemia, unusual bone lesions, and human T-cell leukemia-lymphoma virus in adult T-cell lymphoma. Cancer, 55, 615-619.
281. Taylor, G.P. & Matsuoka, M. (2005) Natural history of adult T-cell leukemia/lymphoma and approaches to therapy. Oncogene, 24, 6047-6057.
282. Tilly, H., Lepage, E., Coiffier, B., Blanc, M., Herbrecht, R., Bosly, A., Attal, M., Fillet, G., Guettier, C., Molina, T.J., Gisselbrecht, C. & Reyes, F. (2003) Intensive conventional chemotherapy (ACVBP regimen) compared with standard CHOP for poor-prognosis aggressive non-Hodgkin lymphoma. Blood, 102, 4284-4289.
283. Tobinai, K., Minato, K., Ohtsu, T., Mukai, K., Kagami, Y., Miwa, M., Watanabe, S. & Shimoyama, M. (1988) Clinicopathologic, immunophenotypic, and immunogenotypic analyses of immunoblastic lymphadenopathy-like T-cell lymphoma. Blood, 72, 1000-1006.
284. Tsatalas, C., Margaritis, D., Kaloutsi, V., Martinis, G., Kotsianidis, I. & Bourikas, G. (2001) Successful treatment of angioimmunoblastic lymphadenopathy with dysproteinemia-type T-cell lymphoma with fludarabine. Acta Haematologica, 105, 106-108.
285. Tse, E., Chan, J.C., Pang, A., Au, W.Y., Leung, A.Y., Lam, C.C. & Kwong, Y.L. (2007) Fludarabine, mitoxantrone and dexamethasone as first-line treatment for T-cell large granular lymphocyte leukemia. leukemia, 21, 2225-2226.
286. Tsimberidou, A.M., Giles, F., Duvic, M., Fayad, L. & Kurzrock, R. (2004) Phase II study of pentostatin in advanced T-cell lymphoid malignancies: update of an M.D. Anderson Cancer Center series. Cancer, 100, 342-349.
287. Tsirigotis, P., Venetis, E., Kapsimali, V., Rontogianni, D., Varvitsioti, E., Pappa, V. & Apostolidis, P. (2003) 2-deoxycoformycin in the treatment of T-large granular lymphocyte leukemia. Leukemia Research, 27, 865-867.
288. Tsukamoto, N., Kojima, M., Hasegawa, M., Oriuchi, N., Matsushima, T., Yokohama, A., Saitoh, T., Handa, H., Endo, K. & Murakami, H. (2007) The usefulness of (18)F-fluorodeoxyglucose positron emission tomography ((18)F-FDG-PET) and a comparison of (18)F-FDG-pet with (67)gallium scintigraphy in the evaluation of lymphoma: relation to histologic subtypes based on the World Health Organization classification. Cancer, 110, 652-659.
289. Tsukasaki, K., Maeda, T., Arimura, K., Taguchi, J., Fukushima, T., Miyazaki, Y., Moriuchi, Y., Kuriyama, K., Yamada, Y. & Tomonaga, M. (1999) Poor outcome of autologous stem cell transplantation for adult T cell leukemia/lymphoma: a case report and review of the literature. Bone Marrow Transplantation, 23, 87-89.
290. Tsukasaki, K., Utsunomiya, A., Fukuda, H., Shibata, T., Fukushima, T., Takatsuka, Y., Ikeda, S., Masuda, M., Nagoshi, H., Ueda, R., Tamura, K., Sano, M., Momita, S., Yamaguchi, K., Kawano, F., Hanada, S., Tobinai, K., Shimoyama, M., Hotta, T. & Tomonaga, M. (2007) VCAP-AMP-VECP compared with biweekly CHOP for adult T-cell leukemia-lymphoma: Japan Clinical Oncology Group Study JCOG9801. Journal of Clinical Oncology, 25, 5458-5464.
291. Tsukasaki, K., Hermine, O., Bazarbachi, A., Ratner, L., Ramos, J.C., Harrington, Jr, W., O'Mahony, D., Janik, J.E., Bittencourt, A.L., Taylor, G.P., Yamaguchi, K., Utsunomiya, A., Tobinai, K. & Watanabe, T. (2009) Definition, prognostic factors, treatment, and response criteria of adult T-cell leukemia-lymphoma: a proposal from an international consensus meeting. Journal of Clinical Oncology, 27, 453-459.
292. Uozumi, K., Nakahara, K., Takatsuka, Y., Ohno, N., Makino, T., Utsunomiya, A., Hanada, S. & Arima, T. (1998) Granulocyte colony-stimulating factor in the combination chemotherapy for adult T-cell leukemia (ATL). Leukaemia & Lymphoma, 29, 407-414.
293. Utsunomiya, A., Miyazaki, Y., Takatsuka, Y., Hanada, S., Uozumi, K., Yashiki, S., Tara, M., Kawano, F., Saburi, Y., Kikuchi, H., Hara, M., Sao, H., Morishima, Y., Kodera, Y., Sonoda, S. & Tomonaga, M. (2001) Improved outcome of adult T cell leukemia/lymphoma with allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplantation, 27, 15-20.
294. Vega, F., Medeiros, L.J. & Gaulard, P. (2007) Hepatosplenic and other gammadelta T-cell lymphomas. American Journal of Clinical Pathology, 127, 869-880.
295. Virgilio, L., Narducci, M.G., Isobe, M., Billips, L.G., Cooper, M.D., Croce, C.M. & Russo, G. (1994) Identification of the TCL1 gene involved in T-cell malignancies. Proceedings of the National Academy of Sciences of the United States of America, 91, 12530-12534.
296. Vose, J., Armitage, J. & Weisenburger, D. (2008) International peripheral T-cell and natural killer/T-cell lymphoma study: pathology findings and clinical outcomes. Journal of Clinical Oncology, 26, 4124-4130.
297. Waldmann, T.A. (2007) Anti-Tac (daclizumab, Zenapax) in the treatment of leukemia, autoimmune diseases, and in the prevention of allograft rejection: a 25-year personal odyssey. Journal of Clinical Immunology, 27, 1-18.
298. Watanabe, J., Kondo, H. & Hatake, K. (2001) Autologous stem cell transplantations for recurrent adult T cell leukaemia/lymphoma using highly purified CD34+ cells derived from cryopreserved peripheral blood stem cells. Leukaemia & Lymphoma, 42, 1115-1117.
299. Watanabe, T., Kinoshita, T., Itoh, K., Yoshimura, K., Ogura, M., Kagami, Y., Yamaguchi, M., Kurosawa, M., Tsukasaki, K., Kasai, M., Tobinai, K., Kaba, H., Mukai, K., Nakamura, S., Ohshima, K., Hotta, T. & Shimoyama, M. (2010) Pretreatment total serum protein is a significant prognostic factor for the outcome of patients with peripheral T/natural killer-cell lymphomas. Leukaemia & Lymphoma, 51, 813-821.
300. Weidmann, E. (2000) Hepatosplenic T cell lymphoma. A review on 45 cases since the first report describing the disease as a distinct lymphoma entity in 1990. Leukemia, 14, 991-997.
301. Weidmann, E., Hess, G., Chow, K.U., Krause, S.W., Subklewe, M., Kruse, J., Weisel, K.C., Soekler, M., Kim, S.Z., Napieralski, S., Rech, J., Dreyling, M., Jager, E. & Mitrou, P.S. (2010) A phase II study of alemtuzumab, fludarabine, cyclophosphamide, and doxorubicin (Campath-FCD) in peripheral T-cell lymphomas. Leukaemia & Lymphoma, 51, 447-455.
302. Went, P., Agostinelli, C., Gallamini, A., Piccaluga, P.P., Ascani, S., Sabattini, E., Bacci, F., Falini, B., Motta, T., Paulli, M., Artusi, T., Piccioli, M., Zinzani, P.L. & Pileri, S.A. (2006) Marker expression in peripheral T-cell lymphoma: a proposed clinical-pathologic prognostic score. Journal of Clinical Oncology, 24, 2472-2479.
303. White, J.D., Zaknoen, S.L., Kasten-Sportes, C., Top, L.E., Navarro-Roman, L., Nelson, D.L. & Waldmann, T.A. (1995) Infectious complications and immunodeficiency in patients with human T-cell lymphotropic virus I-associated adult T-cell leukemia/lymphoma. Cancer, 75, 1598-1607.
304. White, J.D., Wharfe, G., Stewart, D.M., Maher, V.E., Eicher, D., Herring, B., Derby, M., Jackson- Booth, P.G., Marshall, M., Lucy, D., Jain, A., Cranston, B., Hanchard, B., Lee, C.C., Top, L.E., Fleisher, T.A., Nelson, D.L. & Waldmann, T.A. (2001) The combination of zidovudine and interferon alpha-2B in the treatment of adult T-cell leukemia/lymphoma. Leukaemia & Lymphoma, 40, 287-294.
305. Willemze, R., Jaffe, E.S., Burg, G., Cerroni, L., Berti, E., Swerdlow, S.H., Ralfkiaer, E., Chimenti, S., Diaz- Perez, J.L., Duncan, L.M., Grange, F., Harris, N.L., Kempf, W., Kerl, H., Kurrer, M., Knobler, R., Pimpinelli, N., Sander, C., Santucci, M., Sterry, W., Vermeer, M.H., Wechsler, J., Whittaker, S. & Meijer, C.J. (2005) WHO-EORTC classification for cutaneous lymphomas. Blood, 105, 3768-3785.
306. Willemze, R., Jansen, P.M., Cerroni, L., Berti, E., Santucci, M., Assaf, C., Canninga-van Dijk, M.R., Carlotti, A., Geerts, M.L., Hahtola, S., Hummel, M., Jeskanen, L., Kempf, W., Massone, C., Ortiz- Romero, P.L., Paulli, M., Petrella, T., Ranki, A., Peralto, J.L., Robson, A., Senff, N.J., Vermeer, M.H., Wechsler, J., Whittaker, S. & Meijer, C.J. (2008) Subcutaneous panniculitis-like T-cell lymphoma: definition, classification, and prognostic factors: an EORTC Cutaneous Lymphoma Group Study of 83 cases. Blood, 111, 838-845.
307. Witzig, T.E., Weitz, J.J., Lundberg, J.H. & Tefferi, A. (1994) Treatment of refractory T-cell chronic lymphocytic leukemia with purine nucleoside analogues. Leukaemia & Lymphoma, 14, 137-139.
308. Wohrer, S., Chott, A., Drach, J., Puspok, A., Hejna, M., Hoffmann, M. & Raderer, M. (2004) Chemotherapy with cyclophosphamide, doxorubicin, etoposide, vincristine and prednisone (CHOEP) is not effective in patients with enteropathy-type intestinal T-cell lymphoma. Annals of Oncology, 15, 1680-1683.
309. Wulf, G.G., Hasenkamp, J., Jung, W., Chapuy, B., Truemper, L. & Glass, B. (2005) Reduced intensity conditioning and allogeneic stem cell transplantation after salvage therapy integrating alemtuzumab for patients with relapsed peripheral T-cell non-Hodgkin's lymphoma. Bone Marrow Transplantation, 36, 271-273.
310. Yamada, Y., Tomonaga, M., Fukuda, H., Hanada, S., Utsunomiya, A., Tara, M., Sano, M., Ikeda, S., Takatsuki, K., Kozuru, M., Araki, K., Kawano, F., Niimi, M., Tobinai, K., Hotta, T. & Shimoyama, M. (2001) A new G-CSF-supported combination chemotherapy, LSG15, for adult T-cell leukaemia-lymphoma: Japan Clinical Oncology Group Study 9303. British Journal of Haematology, 113, 375-382.
311. Yamaguchi, M., Suzuki, R., Kwong, Y.L., Kim, W.S., Hasegawa, Y., Izutsu, K., Suzumiya, J., Okamura, T., Nakamura, S., Kawa, K. & Oshimi, K. (2008) Phase I study of dexamethasone, methotrexate, ifosfamide, L-asparaginase, and etoposide (SMILE) chemotherapy for advanced-stage, relapsed or refractory extranodal natural killer (NK)/T-cell lymphoma and leukemia. Cancer Science, 99, 1016-1020.
312. Yamaguchi, M., Tobinai, K., Oguchi, M., Ishizuka, N., Kobayashi, Y., Isobe, Y., Ishizawa, K., Maseki, N., Itoh, K., Usui, N., Wasada, I., Kinoshita, T., Ohshima, K., Matsuno, Y., Terauchi, T., Nawano, S., Ishikura, S., Kagami, Y., Hotta, T. & Oshimi, K. (2009) Phase I/II study of concurrent chemoradiotherapy for localized nasal natural killer/T-cell lymphoma: Japan Clinical Oncology Group Study JCOG0211. Journal of Clinical Oncology, 27, 5594-5600.
313. Yong, W., Zheng, W., Zhu, J., Zhang, Y., Wei, Y., Wang, X., Lin, N., Xie, Y., Xu, B. & Li, J. (2006) Midline NK/T-cell lymphoma nasal-type: treatment outcome, the effect of L-asparaginase based regimen, and prognostic factors. Hematological Oncology, 24, 28-32.
314. You, J.Y., Chi, K.H., Yang, M.H., Chen, C.C., Ho, C.H., Chau, W.K., Hsu, H.C., Gau, J.P., Tzeng, C.H., Liu, J.H., Chen, P.M. & Chiou, T.J. (2004) Radiation therapy versus chemotherapy as initial treatment for localized nasal natural killer (NK)/T-cell lymphoma: a single institute survey in Taiwan. Annals of Oncology, 15, 618-625.
315. Zamkoff, K.W., Matulis, M.D., Mehta, A.C., Beaty, M.W., Hutchison, R.E. & Gentile, T.C. (2004) High-dose therapy and autologous stem cell transplant does not result in long-term disease-free survival in patients with recurrent chemotherapy-sensitive ALK-negative anaplastic large-cell lymphoma. Bone Marrow Transplantation, 33, 635-638.
316. Zhao, W.L., Mourah, S., Mounier, N., Leboeuf, C., Daneshpouy, M.E., Legres, L., Meignin, V., Oksenhendler, E., Maignin, C.L., Calvo, F., Briere, J., Gisselbrecht, C. & Janin, A. (2004) Vascular endothelial growth factor-A is expressed both on lymphoma cells and endothelial cells in angioimmunoblastic T-cell lymphoma and related to lymphoma progression. Laboratory Investigation, 84, 1512-1519.
317. Zinzani, P.L., Baliva, G., Magagnoli, M., Bendandi, M., Modugno, G., Gherlinzoni, F., Orcioni, G.F., Ascani, S., Simoni, R., Pileri, S.A. & Tura, S. (2000) Gemcitabine treatment in pretreated cutaneous T-cell lymphoma: experience in 44 patients. Journal of Clinical Oncology, 18, 2603-2606.
318. Zinzani, P.L., Musuraca, G., Tani, M., Stefoni, V., Marchi, E., Fina, M., Pellegrini, C., Alinari, L., Derenzini, E., de Vivo, A., Sabattini, E., Pileri, S. & Baccarani, M. (2007) Phase II trial of proteasome inhibitor bortezomib in patients with relapsed or refractory cutaneous T-cell lymphoma. Journal of Clinical Oncology, 25, 4293-4297.
319. Zinzani, P.L., Stefoni, V., Tani, M., Fanti, S., Musuraca, G., Castellucci, P., Marchi, E., Fina, M., Ambrosini, V., Pellegrini, C., Alinari, L., Derenzini, E., Montini, G., Broccoli, A., Bacci, F., Pileri, S. & Baccarani, M. (2009) Role of [18F]fluorodeoxyglucose positron emission tomography scan in the follow-up of lymphoma. Journal of Clinical Oncology, 27, 1781-1787.